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Cancer	 is	 primarily	 a	 disease	 of	 disordered	 gene	 expression;	 the	 dysregulation	 of	
thousands	of	different	genes	has	been	associated	with	the	progression	of	many	types	of	
cancer.	 Previous	 research	 from	our	 laboratory	 aimed	at	 identifying	 genes	differentially	
expressed	 in	 cervical	 cancer	 compared	 to	normal	patient	 tissue,	 found	Karyopherin	β1	
(Kpnβ1),	the	primary	nuclear	import	protein,	to	be	significantly	overexpressed	in	cervical	
cancer	 tissue.	 Further	 studies	 showed	 that	 inhibition	 of	 Kpnβ1	 expression	 by	 siRNA	
resulted	in	cancer	cell	death,	while	non-cancer	cells	were	only	minimally	affected.	These	






Our	 data	 revealed	 that	 Kpnβ1	 overexpression,	 above	 what	 was	 already	 detected	 in	
cancer	 cells,	 resulted	 in	 reduced	 proliferation	 and	 an	 associated	 delay	 in	 cell	 cycle	
progression.	 Additionally,	 overexpression	 of	 Kpnβ1	 caused	 changes	 in	 the	morphology	
and	adhesion	properties	of	 cells.	Co-expression	of	Ran,	an	 important	nuclear	 transport	
factor,	 binding	 partner	 and	 regulator	 of	 Kpnβ1,	 resulted	 in	 a	 further	 reduction	 in	




Previous	work	from	our	 laboratory	using	a	newly	 identified	small	molecule,	 Inhibitor	of	
Nuclear	Import-43	(INI-43),	showed	that	INI-43	significantly	reduced	the	proliferation	of	
cancer	cells	of	different	tissue	origins	and	interfered	with	the	nuclear	import	function	of	
Kpnβ1.	 In	 order	 to	 investigate	 the	 specificity	 of	 INI-43	 for	 Kpnβ1	 in	 this	 study,	 we	
performed	 experiments	 to	 determine	 whether	 overexpression	 of	 Kpnβ1	 could	 rescue	
cancer	cells	from	the	negative	effects	associated	with	INI-43	treatment.	Results	revealed	







videomicroscopy	 was	 used	 to	 study	 cells	 as	 the	 progressed	 through	 the	 cell	 cycle.	
Inducible	 expression	 of	 Kpnβ1-EGFP,	 as	 well	 as	 the	 treatment	 of	 cells	 with	 the	 small	
molecule	 inhibitor	 INI-43,	were	used	as	mechanisms	of	dysregulation.	Results	 revealed	
that	modulation	of	Kpnβ1	by	either	overexpression	or	 inhibition	caused	a	disruption	 in	
mitotic	progression,	with	the	appearance	of	distinct	mitotic	abnormalities.	The	treatment	




for	 the	 correct	 functioning	 of	 cancer	 cells;	 when	 the	 balance	 is	 perturbed	 in	 either	
direction	 (i.e.	 with	 overexpression	 of	 Kpnβ1	 or	 INI-43-mediated	 inhibition	 of	 Kpnβ1)	
	 xvi	
negative	 effects	 associated	 with	 a	 variety	 of	 biological	 processes	 are	 observed.	 In	













Cancer	 is	 a	 leading	 cause	 of	mortality	worldwide.	 According	 to	 a	 report	 issued	 by	 the	
International	 Agency	 for	 Research	 on	 Cancer	 (IARC),	 in	 2012	 the	 global	 cancer	 burden	
was	 documented	 as	 14.1	 million	 new	 cases	 per	 year,	 with	 an	 expectation	 to	 rise	 to									
22	million	new	cases	within	the	next	two	decades.	By	the	year	2032,	cancer	deaths	are	
predicted	 to	 have	 risen	 from	 8.2	 million	 to	 13	 million	 deaths	 per	 annum,	 with	 a	
disproportionate	70%	of	these	deaths	occurring	in	less	developed	countries1.	Increasing	
numbers	 in	 global	 cancer	 incidence	 and	 mortality	 stress	 the	 urgency	 and	 need	 for	













a	peak	 in	1991,	 cancer	death	 rates	 in	 the	United	States	have	declined	by	22%,	and	an	
approximate	83%	improvement	in	cancer	survival	rates	can	be	largely	attributed	to	new	
treatments5,6.	Despite	 these	 figures,	 treatment	options	 for	a	wide	range	of	cancers	are	
still	limited	and	the	need	for	novel	anti-cancer	therapeutics	remains	urgent.	
	
Targeted	 therapies	 are	 currently	 the	 focus	 of	 many	 cancer	 research	 groups	 and	
pharmaceutical	companies,	whose	aim	is	to	identify	novel	anti-cancer	therapeutics	with	
higher	efficacy	and	limited	side	effects.	While	traditional	chemotherapy	involves	the	use	
of	 chemical	 agents	 to	 target	 all	 rapidly	 dividing	 cells	 (normal	 and	 cancerous),	 targeted	
therapy	refers	 to	the	use	of	drugs	designed	to	 interfere	with	specific	molecular	 targets	
associated	with	cancer	development	and	progression2.	The	intention	is	to	 limit	the	side	
effects	 commonly	 associated	with	 conventional	 chemotherapy	 by	 specifically	 targeting	
and	killing	cancer	cells,	thereby	limiting	associated	toxicities	to	non-cancer	cells.	Perhaps	
one	 of	 the	most	 successful	 targeted	 therapies	 identified	 to	 date	 is	 the	 tyrosine	 kinase	
inhibitor	imatinib	mesylate	(Gleevec),	which	targets	and	inhibits	the	kinase	fusion	protein	
Bcr-Abl	 in	 chronic	myeloid	 leukaemia	 (CML).	 	The	constitutive	activation	of	 the	Bcr-Abl	
fusion	 protein	 is	 both	 essential	 and	 sufficient	 for	 malignant	 transformation	 and	 CML,	
thus	 treatment	 with	 Gleevec	 allows	 for	 specific	 targeting	 of	 leukaemic	 cancer	 cells	
only7,8.		
	
Despite	 advances	 in	 cancer	 associated	 biomedical	 research,	 which	 have	 lead	 to	 the	
development	 of	 Gleevec	 and	 other	 successful	 therapeutics,	 the	 productivity	 of	











and	proteomic	 techniques	 to	 identify	molecular	 targets,	 in	an	attempt	 to	develop	new	
and	improved	anti-cancer	therapeutics11.	Among	many	of	the	high-throughput	methods	
used	in	cancer	drug	discovery	efforts,	transcriptional	profiling	remains	an	important	tool	
in	 determining	 the	 genetic	 abnormalities	 and	 complexities	 associated	 with	 cancer.	
Genome-wide	 expression	 based	 microarrays,	 a	 powerful	 screening	 technique	 used	 to	
assess	 and	 compare	 the	 gene	 expression	 profiles	 of	 two	 different	 biological	 states	 (ie.	
cancer	versus	normal	tissue),	represent	a	technique	commonly	used	in	the	identification	
of	genes	involved	in	cancer	development	and	progression12.	Genes	that	are	differentially	
expressed	 in	 cancer	 compared	 to	 normal	 tissue	 present	 as	 potential	 targets	 for	 novel	
therapies.	Over	 the	 past	 few	 years,	 there	 has	 been	 a	 rapid	 increase	 in	 the	 number	 of	
studies	using	DNA	microarrays	 to	 identify	critical	genes	 involved	 in	carcinogenesis,	and	
many	publications	have	revealed	evidence	for	genes	that	play	a	role	in	cancer	initiation,	
metastasis	and	survival.	Furthermore,	microarray	technology	has	been	useful	in	defining	
the	 gene	 expression	 changes	 associated	 with	 drug	 treatment	 and	 acquired	 drug-
resistance	in	cancer	cells,	which	has	resulted	in	the	discovery	of	novel	molecular	targets,	
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cancer	 versus	 normal	 cervical	 tissue	 from	 a	 South	 African	 cohort	 of	 patients	 was	
performed	 to	 identify	 genes	 that	 associate	 with	 the	 development	 of	 cervical	 cancer.	
Comparison	 of	 the	 expression	 profiles	 revealed	 a	 large	 number	 of	 genes	 showing	
differential	 expression,	 among	 them	Karyopherin	 β1	 (Kpnβ1),	 Karyopherin	α2	 (Kpnα2),	
and	CRM1	–	members	of	the	Karyopherin	superfamily	of	nuclear	transport	proteins	–	and	
Ran,	were	found	to	be	significantly	overexpressed	in	cervical	cancer	tissues.	Subsequent	
research	 showed	 that	 inhibition	of	Kpnβ1	and	CRM1	expression	 resulted	 in	 cancer	 cell	
death,	 revealing	 both	 proteins	 as	 potential	 anti-cancer	 therapeutic	 targets14.	 In	 recent	







The	 nucleus	 in	 all	 eukaryotic	 cells	 is	 enclosed	 by	 the	 nuclear	 envelope,	 a	 double	 lipid	
bilayer	membrane	that	divides	the	cells	into	two	compartments,	between	which	there	is	
an	 interchange	 of	 proteins	 and	 RNAs	 into	 and	 out	 of	 the	 nucleus.	 This	
compartmentalisation	 of	 molecules	 is	 important,	 as	 it	 maintains	 cell	 homeostasis	 by	
allowing	 for	 spatial	 separation,	 and	 thus	 control,	 of	 important	 cellular	 processes;	
transcription	 factors	 and	 histones	 need	 to	 enter	 the	 nucleus	 in	 order	 to	 induce	 gene	
5	
expression	and	 formation	of	nucleosome,	 respectively,	while	mRNAs,	 tRNAs	and	rRNAs	
that	 are	 transcribed	 in	 the	 nucleus	 need	 to	 be	 exported	 to	 the	 cytoplasm	 in	 order	 to	
function	in	translation16.		




40kDa	 in	 size)	 have	 the	 ability	 to	 passively	 diffuse	 through	 the	NPC16.	 The	NPC,	which	
represents	one	of	the	largest	protein	structures	in	the	eukaryotic	cell,	 is	composed	of	a	
set	 of	 approximately	 30	 different	 proteins	 called	 nucleoporins	 (Nups),	 which	 are	
constructed	primarily	of	one	or	more	of	the	following	structural	units:	α-helical	regions,	
β-propellar	 and	 α-solenoid	 folds,	 and	 tandem	 repeated	 phenylalanine-glycine	 (FG)	
motifs.	These	motifs	 (also	called	FxFG	 repeats)	 line	 the	active	 transport	 channel	of	 the	
NPC	and	serve	as	docking	sites	for	transport	receptors17–19.		
The	 NPC,	 in	 collaboration	 with	 the	 Ras-related	 nuclear	 protein	 (Ran)	 and	 Karyopherin	
nuclear	 transport	 proteins,	 collectively	 known	 as	 the	 nuclear	 transport	machinery,	 are	
critically	 important	 for	 the	 shuttling	 of	 cargo	molecules	 between	 the	 nucleus	 and	 the	
cytoplasm.	 Disruption	 of	 the	 nuclear	 transport	 process	 leads	 to	 inappropriate	 spatial	





The	 Karyopherin	 protein	 superfamily	 consists	 of	 a	 large	 number	 of	 soluble	 transport	
factors	that	shuttle	proteins	and	certain	RNAs	through	the	NPC.	Studies	have	shown	that	
in	 addition	 to	 their	 roles	 as	 nuclear	 transporters,	 the	 Karyopherins	 play	 vital	 roles	 in	




classified	on	the	basis	of	 the	direction	 in	which	they	carry	their	cargo.	Members	of	 the	




which	 most	 commonly	 consists	 of	 a	 number	 of	 clusters	 of	 basic	 amino	 acids	 and	 is	
termed	 the	 classical	 NLS	 (cNLS),	 by	 a	 Kpnα	 isoform	 is	 required	 for	 Kpnβ1-mediated	
nuclear	 import;	Kpnβ1	 is	 the	main	nuclear	 import	protein	 in	 interphase	cells	 23,24.	After	
Kpnα	binds	to	the	NLS-containing	cargo,	forming	a	bridge	between	the	cargo	and	Kpnβ1,	
Kpnβ1	interacts	with	FG-Nups	on	the	NPC	to	allow	for	transfer	of	the	cargo	through	the	
channel.	Once	 in	 the	nucleus,	 binding	of	RanGTP	 results	 in	 dissociation	of	 the	 trimeric	
complex	 and	 release	 of	 the	 cargo25.	 Kpnβ1	 and	 Kpnα	 are	 then	 recycled	 back	 to	 the	




Nuclear	 export	 proteins,	 or	 exportins,	 bind	 to	 cargo	 molecules	 containing	 a	 nuclear	
export	 signal	 (NES).	 The	 classical	 nuclear	 export	 pathway	 involves	 the	 exportin	 CRM1	
binding	 directly	 to	 NES-containing	 cargoes,	which	 in	 the	 presence	 of	 RanGTP,	 exit	 the	
nucleus	via	the	NPC.	Hydrolysis	of	RanGTP	to	RanGDP	promotes	the	dissociation	of	the	
CRM1	complex,	and	subsequent	release	of	 the	cargo	 into	the	cytoplasm.	CRM1	 is	 then	




Figure	1.1.	A	simplified	schematic	 showing	 the	classical	nuclear	 import	and	export	pathways.	
NLS-containing	cargo,	Kpnα	and	Kpnβ1	form	a	trimeric	complex	and	are	transported	through	the	








Ran,	 a	 small	 Ras-related	nuclear	 guanosine	 triphosphatase	 (GTPase),	 is	 required	 for	 all	
forms	 of	 active	 nuclear	 import	 and	 export;	 it	 provides	 energy	 and	 determines	








In	 the	 classical	 nuclear	 import	 pathway,	 the	 cargo:Kpnα:Kpnβ1	 trimeric	 complex	
dissociates	 in	 the	 nucleus	 when	 RanGTP	 binds	 to	 Kpnβ1	 through	 its	 conserved	 Ran	
binding	domain,	thereby	releasing	the	cargo	and	terminating	nuclear	import.	Kpnβ1	and	
Kpnα	 are	 recycled	 to	 the	 cytoplasm;	 Kpnβ1	 bound	 by	 RanGTP	 and	 Kpnα	 bound	 by	 its	
own	 nuclear	 exporter,	 the	 cellular	 apoptosis	 susceptibility	 protein,	 CAS	 (or	 CSE1L)	 and	
RanGTP30.	 Once	 in	 the	 cytoplasm,	 RanGTP	 is	 hydrolysed	 to	 RanGDP	 by	 RanGAP1	 and	






For	 nuclear	 export	 to	 occur,	 RanGTP	 binds	 to	 exportin	 proteins	 such	 as	 CRM1	 in	 the	
nucleus,	which	promotes	assembly	and	docking	of	 the	export	complex	at	 the	NPC.	The	
hydrolysis	of	RanGTP	to	RanGDP	in	the	cytoplasm,	promoted	by	RanGAP1	and	assisted	by	






While	 some	 proteins	 are	 able	 to	 enter	 or	 exit	 the	 nucleus	 without	 the	 help	 of	 the	
Karyopherin	proteins,	a	considerably	 larger	proportion	of	proteins	rely	on	Karyopherin-
mediated	nuclear	transport	across	the	NPC.	The	Karyopherin	proteins	are	responsible	for	
the	 transport	 of	 multiple	 transcription	 factors,	 including	 NFκB34,	 NFAT35,	 c-Jun36	 and	
STAT37.	These	proteins	are	translated	in	the	cytoplasm	but	are	only	active	in	the	nucleus,	
where	 they	 can	 bind	 to	 the	 promoters	 of	 their	 target	 genes,	 resulting	 in	 activation	 or	
repression	of	gene	expression.		
	
NFκB,	 which	 is	 involved	 in	 a	 range	 of	 biological	 processes,	 relies	 primarily	 on	 nuclear	
import	mediated	by	Kpnα2	in	complex	with	Kpnβ1	to	enter	the	cell	nucleus	to	regulate	
expression	 of	 its	 target	 genes.	 Aberrant	 or	 constitutive	 NFκB	 expression	 leads	 to	 the	
uncontrolled	expression	of	genes	involved	in	the	regulation	of	cellular	processes	such	as	
proliferation,	migration,	 apoptosis,	 and	 cell	 cycle	 control,	which	 can	 ultimately	 lead	 to	
the	development	and	progression	of	cancer38–40.	In	the	classical	NFκB	pathway,	the	NLS	is	
masked	 from	 recognition	 by	 the	 Kpnβ1:Kpnα2	 complex	 due	 to	 binding	 of	 an	 inhibitor	
protein	IκB,	which	holds	it	in	an	inactive	state	in	the	cytoplasm.	Upon	NFκB	activation,	via	
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the	nuclear	 import	of	 specific	downstream	proteins	 such	as	kinases,	phosphatases	and	
various	 transcription	 factors.	 	 For	 example,	 phosphorylated	 ERK,	 a	 component	 of	 the	
MAPK	pathway,	enters	the	nucleus	via	Kpnβ1-mediated	import41.	Many	proteins	involved	
in	 the	 cell	 cycle	 also	 rely	 on	 Karyopherin-mediated	 transport	 to	 fulfill	 their	 roles.	 For	
example,	 Cdk2/cyclin	 E	 and	Cdc2/cyclin	B1	 are	 imported	 into	 the	nucleus	by	Kpnβ1	 to	
perform	time-dependent	phosphorylation	of	their	substrates42.		
	
Various	 tumour	 suppressor	 proteins	 have	 also	 been	 shown	 to	 make	 use	 of	 the	
Karyopherin	 proteins	 for	 their	 nuclear	 import	 and	 export,	 including	 p53,	 BRCA1	 and	
APC43.	The	tumour	suppressor	p53,	which	has	multiple	functions	including	the	regulation	
of	DNA	 replication,	DNA	 repair	 and	 cell	 cycle	 checkpoint,	 exerts	 its	 tumour	 suppressor	
function	 by	 binding	 to	 specific	 promoter	 sequences	 in	 the	 nucleus44.	 p53	 contains	




It	 is	 evident	 that	 the	 Karyopherin	 proteins	 play	 a	 crucial	 role	 in	 the	 recognition	 and	
shuttling	of	a	variety	of	cargo	proteins	across	the	NPC.	Dysregulation	of	nuclear	transport	
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of	 cancer	 cells15.	 Kuusisto	 et	 al.	 (2012)	 showed	 that	 accumulation	 of	 NLS-containing	
proteins	 is	 increased	 up	 to	 7-fold	 in	 transformed	 cells,	 correlating	 with	 increased	
expression	 of	 the	 Karyopherin	 proteins46.	 It	 is	 likely	 that	 transformed	 and	 cancer	 cells	




to	 their	 sites	 of	 action	 can	 be	 regulated	 at	 multiple	 points.	 Thus,	 any	 alterations	 or	




the	 regulation	 of	 nuclear	 transport,	 including	 the	 intermolecular	 and	 intramolecular	
masking	of	nuclear	localisation	and	nuclear	export	signals	(NLSs	and	NESs),	modification	
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of	 the	 enzymes	 controlling	 the	 Ran	 gradient,	 modifications	 in	 the	 composition	 and	
architecture	of	the	NPC,	as	well	as	changes	in	gene	expression	of	members	of	the	nuclear	
transport	 machinery,	 such	 as	 the	 nucleoporins	 and	 Karyopherins48,49.	 	 With	 particular	
reference	 to	 the	Karyopherin	proteins,	 altered	expression	and	 localisation	are	 typically	
associated	 with	 the	 dysregulation	 of	 nuclear	 transport	 that	 is	 commonly	 observed	 in	
cancer	 cells15.	 For	 example,	 van	 der	 Watt	 et	 al.	 (2011)	 recently	 showed	 that	
overexpression	of	both	Kpnβ1	and	Kpnα2	in	cervical	cancer	cells	correlates	with	altered	
transcriptional	regulation	due	to	impaired	E2F/Rb	activity,	which	has	been	shown	to	be	
dysregulated	 in	 the	 vast	 majority	 of	 human	 cancers50,51.	 In	 terms	 of	 localisation,	 the	
ability	of	the	Karyopherins	to	perform	their	function	depends	on	their	ability	to	interact	
appropriately	with	 cargoes	 and	 other	members	 of	 the	 transport	machinery.	 Kim	et	 al.	
(2000)	described	how	a	 truncated	 from	of	Kpnα	 lacking	part	of	 its	NLS-binding	domain	
was	unable	to	bind	and	transport	its	cargo	(p53)	into	the	nucleus	in	breast	cancer	cells.	In	
fact,	 despite	 having	 an	 intact	 Kpnβ1-binding	 domain,	 the	 truncated	 form	of	 Kpnα	was	
predominantly	 located	 to	 the	 cytoplasm	 (as	 opposed	 to	 wild-type	 Kpnα	 being	 evenly	














current	 drugs	 targeting	 these	 proteins	 are	 limited	 and	 further	 research	 needs	 to	 be	
conducted	 toward	 the	 development	 of	 improved	 Karyopherin	 inhibitors.	 There	 are	 a	
number	 of	 problems	 that	 arise	 when	 implicating	 drug	 design	 with	 targeting	 of	 the	
nuclear	transport	process,	for	example;	normal	and	cancer	cells	share	the	same	nuclear	
transport	machinery,	thus	inhibition	of	certain	components	may	have	negative	effects	on	





While	 evidence	 points	 to	 the	 potential	 of	 Kpnβ1	 as	 an	 anti-cancer	 therapeutic	 target,	
CRM1	is	currently	the	only	Karyopherin	protein	that	has	been	extensively	investigated	as	
a	target	for	the	development	of	novel	anti-cancer	therapies.	Leptomycin	B	(LMB)	was	the	
first	 anti-CRM1	 compound	 to	 display	 anti-cancer	 activity	 both	 in	 vitro	 and	 in	 vivo53,54.	
Despite	promising	initial	findings	however,	LMB	was	eventually	discontinued	due	to	high	
toxicity	in	phase	I	clinical	trials	and	subsequent	analogues	have	shown	very	little	clinical	
promise55.	 More	 recently,	 a	 number	 of	 compounds	 known	 collectively	 as	 selective	
inhibitors	 of	 nuclear	 export	 (SINE)	 have	 been	 developed	 and	 tested	 as	 more	 specific	
inhibitors	 of	 CRM1	 that	 show	 fewer	 off-target	 effects.	 Their	 mechanism	 of	 action	 is	
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through	 irreversibly	 binding	 the	 cysteine	 528	 residue	 in	 the	 cargo-binding	 groove	 of	
CRM1,	 thereby	 preventing	 its	 nuclear	 export	 ability56.	 One	 particular	 compound,	
Selinexor	(KPT-330),	has	been	particularly	successful	 in	 in	vitro	and	 in	vivo	studies	for	a	
wide	variety	of	cancer	types,	and	is	now	being	evaluated	in	multiple	clinical	trials57.	The	
success	 associated	 with	 the	 targeting	 of	 CRM1	 using	 this	 group	 of	 compounds	 has	
highlighted	 the	potential	of	 targeting	 the	Karyopherin	proteins	 for	 the	development	of	
novel	anti-cancer	therapies.	
	




are	 Ivermectin,	 Karyostatin	 1A	 and	 Importazole.	 Ivermectin	 was	 first	 identified	 as	 a	
broad-spectrum	 anti-parasitic	 agent	 that	 only	 later	 was	 found	 to	 inhibit	 Kpnα/β-
mediated	 nuclear	 import.	 No	 effect	 on	 other	 nuclear	 import	 pathways,	 such	 as	 those	
mediated	 by	 Kpnβ1	 alone,	 has	 been	 found58.	 The	 first	 novel	 compounds	 found	 to	
interfere	 specifically	 with	 Kpnβ1-mediated	 nuclear	 import	 were	 the	 small	 molecule	
inhibitors	Karyostatin	1A	and	 Importazole,	which	have	both	been	shown	to	disrupt	 the	





Overall,	 drugs	 targeting	 Karyopherin-mediated	 nuclear	 transport	 have	 shown	 potential	






Karyopherin	 β1	 (Kpnβ1;	 also	 known	 as	 Importin	 β	 or	 p97)	 is	 a	 member	 of	 the	
Karyopherin	 superfamily	of	nuclear	 transport	proteins.	 It	was	 first	discovered	by	Adam	
and	 Adam	 (1994)	 as	 soluble	 factor	 required	 for	 NLS-mediated	 binding	 to	 the	 nuclear	
envelope,	and	Görlich	et	al.	(1995)	and	Chi	et	al.	(1995)	later	independently	cloned	it	and	
characterised	its	mechanism	of	action	using	 in	vitro	nuclear	import	assays61–63.	Kpnβ1	is	
an	 876	 amino	 acid	 (or	 97kDa)	 protein	 with	 a	 right-handed	 superhelical	 structure	
consisting	 of	 19	 HEAT	 repeat	 units.	 Each	 unit	 consists	 of	 an	 A	 and	 B	 helix	 that	 is	
connected	by	a	short	turn;	in	HEAT-8	this	is	replaced	by	an	acidic	loop	that	is	critical	for	
the	regulation	of	Kpnβ1	substrate	binding	and	release64.	The	N-terminal	region	of	Kpnβ1	
(comprising	 HEAT	 repeats	 1-8)	 is	 crucial	 for	 binding	 to	 RanGTP,	 while	 the	 central	 and						










HEAT	 repeat	 units,	 each	 of	 which	 comprises	 an	 A	 and	 B	 helix	 separated	 by	 a	 short	 turn.	 In					





Kpnβ1	 was	 initially	 identified	 and	 characterised	 as	 the	 major	 nuclear	 import	 protein	
responsible	 for	 transporting	 NLS-containing	 cargoes	 through	 the	 NPC	 into	 the	 cell	
nucleus,	 however,	 in	 more	 recent	 years	 a	 number	 of	 additional	 roles	 have	 emerged.	
During	mitosis,	Kpnβ1	adopts	an	entirely	different	(but	equally	vital)	set	of	functions,	by	













Targeting	 of	 the	 Karyopherin	 proteins	 for	 the	 development	 of	 novel	 anti-cancer	
therapeutics	has	received	a	significant	amount	of	attention	over	the	last	decade,	with	a	
number	 of	 promising	 clinical	 candidates,	 such	 as	 the	 anti-CRM1	 SINE	 compounds,	
emerging.	This	area	of	 study	 is	 still	however	 in	 its	early	 stages;	until	quite	 recently	 the	
potential	for	Kpnβ1	as	an	anti-cancer	target	had	been	somewhat	underexplored.	Using	a	
cervical	cancer	model,	research	from	our	laboratory	was	the	first	to	show	that	Kpnβ1	is	
overexpressed	 in	 cervical	 cancer	 compared	 to	normal	 cells	 and	 tissue,	 and	 that	 Kpnβ1	
silencing	 by	 siRNA	 resulted	 in	 cancer	 cell	 death14.	 Subsequently,	 enhanced	 Kpnβ1	
expression	 has	 been	 reported	 in	 a	 wide	 variety	 of	 human	 cancers,	 including	 ovarian	
cancer72,	 breast	 carcinoma73,	 myeloma74,	 hepatocellular	 carcinoma75,	 gastric	 cancer76,	
head	 and	 neck	 squamous	 cell	 carcinoma	 and	 lung	 cancer77,	 and	 a	 number	 of	 these	








In	 addition	 to	 its	 potential	 as	 an	 anti-cancer	 target,	 there	 is	 evidence	 emerging	 that	
Kpnβ1	may	be	 useful	 as	 a	 biomarker.	 A	 number	 of	 studies	 have	 revealed	 the	 possible	
prognostic	 use	 of	 Kpnβ1:	 Kuusisto	 et	 al.	 (2015)	 showed	 that	 the	 extent	 of	 Kpnβ1	
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overexpression	correlates	with	diseased	state	in	an	MCF10	human	breast	tumour	model;	
Zhu	et	al.	 (2016)	and	Yang	et	al.	 (2015)	showed	that	Kpnβ1	expression	 levels	positively	
correlate	 with	 tumour	 grade,	 infiltration	 and	 Ki-67	 grade	 in	 gastric	 cancer,	 and	
histological	grade,	metastasis,	vein	invasion	and	tumour	size	in	hepatocellular	carcinoma,	
respectively75,76.	No	 study	 to	 date	 has	 explored	 the	potential	 of	 Kpnβ1	 as	 a	 diagnostic	




variety	 of	 cancer	 types.	 Preliminary	work	 from	 our	 laboratory	 has	 identified	 Kpnβ1	 as	
one	of	several	nuclear	transport	proteins	that	is	secreted	at	higher	levels	in	cancer	versus	







In	 order	 to	 identify	 small	 molecules	 with	 the	 potential	 to	 bind	 and	 inhibit	 Kpnβ1,	 a	
structure-based	 in	 silico	 screen	was	performed	 in	collaboration	with	 researchers	at	 the	
Molecular	Modeling	 Facility	 of	 the	 James	 Graham	 Brown	 Cancer	 Centre	 (University	 of	
Louisville,	 Kentucky,	 USA)52.	 Based	 on	 known	 crystal	 structures,	 a	 rational	 structure-








classical	 NLS-containing	 cargoes25.	 	 Forty-seven	 of	 the	 top-scoring	 compounds	 were	
chosen	according	 to	 their	predicted	Kpnβ1-binding	affinity,	and	 further	 tested	 for	 their	
ability	 to	 block	 nuclear	 import,	 as	 well	 as	 their	 effects	 on	 cancer	 versus	 normal	 cell	
viability.	Of	the	forty-seven	compounds	that	were	tested,	3-(1H-benzimidazol-2-yl)-1-(3-
dimethylaminopropyl)pyrrolo[5,4-b]quinoxalin-2-amine),	which	was	subsequently	named	
Inhibitor	 of	 Nuclear	 Import-43	 (INI-43),	 was	 identified	 as	 one	 of	 the	 best	 candidate	
inhibitors	of	nuclear	import.	This	was	due	to	the	fact	that,	in	addition	to	its	potential	to	
bind	 and	 inhibit	 Kpnβ1,	 INI-43	 was	 found	 to	 be	 more	 effective	 at	 killing	 cancer	 and	
transformed	cells	than	normal	fibroblast	cells,	with	an	EC50	value	(half	maximal	effective	
concentration)	 of	 approximately	 10	 µM,	 which	 is	 within	 the	 range	 of	 known	
chemotherapeutic	agents	such	as	cisplatin,	when	treating	cancer	cells	in	culture.	
	
INI-43	 is	 a	 quinoxaline	 derivative,	 a	 heterocyclic	 compound	 containing	 a	 benzene	 ring	
and	a	pyrazine	ring,	that	has	an	additional	benzimidazole	and	specific	R-group	attached	
(Figure	 1.3).	 Interestingly,	 both	 benzimidazole	 and	 quinoxaline	 structures	 have	 been	
found	 to	 display	 anti-cancer	 activity84,85.	 Recent	 work	 conducted	 in	 our	 laboratory	
showed	that	 INI-43	 interfered	with	the	nuclear	 localisation	of	Kpnβ1	and	known	Kpnβ1	
cargoes	 including	NFκB,	NFAT,	NFY	 and	AP-1,	 and	 inhibited	 the	proliferation	of	 cancer	
cells	 of	 different	 tissue	origins	while	 only	minimally	 affecting	 normal	 cells.	 In	 addition,	
intraperitoneal	administration	of	INI-43	significantly	inhibited	tumour	growth	in	cervical	

















Dysregulation	of	 the	nuclear	 transport	process	 is	directly	associated	with	many	human	
cancers,	 thus	 targeting	 members	 of	 the	 nuclear	 transport	 machinery,	 specifically	 the	
Karyopherin	 protein	 family,	 has	 shown	 potential	 for	 the	 development	 of	 novel	 anti-
cancer	therapeutics.	While	previous	research	has	revealed	that	Kpnβ1	is	overexpressed	
in	 various	 cancers,	 and	 is	 required	 for	 cancer	 cell	 proliferation,	 it	 remains	 unclear	
whether	 upregulation	 of	 Kpnβ1	 induces	 any	 features	 of	 the	 transformed	 or	 cancer	
phenotype.	This	study	further	elucidates	the	relationship	between	Kpnβ1	and	the	cancer	
phenotype	 by	 investigating	 the	 biological	 effects	 associated	 with	 modulating	 Kpnβ1	
expression	 using	 two	 approaches:	 overexpression	 and	 small	 molecule-mediated	









I. To	determine	 the	biological	 implications	of	Kpnβ1	overexpression	 in	cancer	and	
normal	cells.	
	
















(Rockville,	MD,	USA):	human	cervical	 carcinoma	cell	 lines,	HeLa	and	CaSki.	 FG0	normal	
skin	fibroblasts	were	obtained	from	the	Department	of	Medicine,	UCT.	The	HeLa	TET-ON	
Kpnβ1-GFP	 cell	 line	 was	 generated	 by	 Annalisa	 Verrico	 and	 Patrizia	 Lavia	 (Institute	 of	
Molecular	Biology	and	Pathology,	National	Research	Council	of	Italy,	Rome,	Italy).	HeLa,	
CaSki	and	FG0	cells	were	maintained	 in	complete	medium:	Dulbecco’s	Modified	Eagle’s	
Medium	 (DMEM)	 (Gibco,	 Life	 Technologies,	 Carlsbad,	 CA,	 USA)	 supplemented	 with	
penicillin	 (100	 U/ml),	 streptomycin	 (100	 μg/ml)	 and	 10%	 Fetal	 Bovine	 Serum	 (FBS)	
(HyClone	 Laboratories,	 UT,	 USA).	 HeLa	 TET-ON	 Kpnβ1-GFP	 cells	 were	 maintained	 in	
DMEM	supplemented	with	penicillin	(100	U/ml),	streptomycin	(100	μg/ml)	and	10%	FBS	








Kpnβ1	 overexpressing	 HeLa	 and	 CaSki	 cells	 (pEFIRES-Kpnβ1-EGFP)	 and	 control	 cells	
(pEFIRES-EGFP)	were	established	using	 the	pEFIRES	construct	as	previously	described52.	
The	 pEFIRES	 plasmid	was	 a	 kind	 gift	 from	Yosef	 Shaul	 (Weizmann	 Institute	 of	 Science,	
Isreal)86,	 and	 the	Kpnβ1	 sequence	was	 released	 from	 the	pEGFP-Kpnβ1	plasmid,	which	
was	 kindly	 donated	 by	 Patrizia	 Lavia	 (Institute	 of	 Molecular	 Biology	 and	 Pathology,	
National	Research	Council	of	Italy,	Rome,	Italy)87.		
	
The	Ran-EGFP	plasmid	 for	 overexpression	was	 created	by	Dr	 Pauline	 van	der	Watt,	 by	
amplifying	 the	 Ran	 coding	 sequence	 from	CaSki	 cDNA	 using	 sequence	 specific	 primers	
(forward:	5’	AGCTCGAGGATGGCTGCGCAGGGAGAG	3’,	reverse:	5’	AGGGATCCTCACAGGT	








Inhibitor	 of	 Nuclear	 Import-43,	 INI-43	 (3-(1H-benzimidazol-2-yl)-1-(3-dimethylamino-
propyl)pyrrolo[5,4-b]quinoxalin-2-amine)	was	obtained	in	powder	form	from	Chembridge	
(ZINC	 identification	 number	 20547783,	 San	 Diego,	 CA,	 USA).	 The	 compound	 was	
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Puromycin	was	 purchased	 from	 Calbiochem	 (Merck	Millipore,	 Billerica,	MA,	 USA),	 and	


























30	 μl	 of	E.coli	 JM109	 competent	 cells	 (Promega,	Madison,	WI,	USA),	which	were	 then	
incubated	on	ice	for	10-30	minutes.	The	cells	were	heat	shocked	at	42°C	for	2	minutes	in	
order	to	aid	plasmid	uptake.	0.45	ml	of	Luria	Broth	(LB)	medium	was	added	to	the	heat-
shocked	cells,	which	were	 then	 incubated	at	37°C	 for	1	hour,	with	 shaking.	100	μl	and	
400	μl	of	the	broth	was	then	plated	onto	two	separate	100	μg/ml	ampicillin-containing	
LB	agar	plates,	and	incubated	overnight	at	37°C.	The	following	day,	a	colony	was	picked	








Plasmid	 extraction	 was	 performed	 according	 to	 the	 QIAGEN	 Plasmid	 Maxikit	








To	 confirm	 amplification	 of	 the	 correct	 plasmid	 DNA,	 restriction	 enzyme	 digests	 were	
performed.	 The	 restriction	 enzymes	 SacI	 and	 BamHI	 (Fermentas,	 Thermo	 Fischer	
Scientific,	Weltham,	MA,	 USA)	 were	 used	 to	 linearise	 the	 plasmid,	 and	 in	 the	 case	 of	
Kpnβ1-EGFP,	release	the	Kpnβ1-encoding	fragment.	For	digestion,	1	μg	plasmid	DNA	was	
digested	by	1	μl	SacI	and	 BamHI,	 in	a	 final	 volume	of	20	μl	dH20	with	2	μl	 Fast	Digest	
Green	Buffer	(Fermentas).	The	mix	was	incubated	at	37°C	for	2	hours,	before	running	the	
digestion	on	a	1%	agarose	gel.	 The	gel	was	 run	 in	TBE	buffer	at	100	V	 for	1	hour,	and	













HeLa	 and	 CaSki	 cells	 using	 Genecellin	 Transfection	 Reagent	 (BioCellChallenge,	 Toulon,	
France),	 and	 thereafter	 positively	 transfected	 cells	 were	 selected	 using	 Puromycin	
(Calbiochem).	Pools	of	stably	transfected	cells	were	maintained	in	0.5	μg/ml	Puromycin.	

















































Cells	 in	 culture,	 grown	 to	 80%	 confluency	 or	 subjected	 to	 the	 required	 treatment	 or	
transfection,	were	 lysed	 in	 radioimmunoprecipitation	assay	 (RIPA)	buffer	 containing	1X	

























































PBS,	 followed	 by	 the	 addition	 of	 RIPA	 buffer.	 Cells	 were	 harvested	 by	 scraping,	 and	
collected	into	sterile	eppendorf	tubes.	Protein	extracts	were	sonicated	for	10	seconds	to	
shear	DNA,	 followed	by	centrifugation	at	10000	x	g	at	4°C	to	pellet	cellular	debris.	The	























SDS	 polyacrylamide	 gels	 were	 prepared	 with	 4%	 stacking	 gels	 set	 above	 10%	 -	 15%	
separating/resolving	gels.	Depending	on	the	concentration	of	the	sample,	10-30	μg	of	the	
extracted	 protein	 suspended	 in	 RIPA	 buffer,	 along	 with	 1X	 Laemmli	 Loading	 Dye	
containing	10%	β-mercaptoethanol,	was	denatured	at	90°C	for	5	minutes,	before	loading	








Proteins	 were	 transferred	 from	 the	 SDS	 polyacrylamide	 gel	 to	 a	 HyBondTM-ECLTM	
nitrocellulose	 membrane	 (Amersham,	 Buckinghamshire,	 UK)	 in	 1X	 transfer	 buffer	 at				
100	V	for	70	minutes.	The	membrane	was	then	blocked	in	5%	non-fat	dry	milk	(NFDM)	in	
TBST,	 for	 1	 hour	 at	 room	 temperature	 with	 shaking,	 in	 order	 to	 prevent	 non-specific	
binding	 of	 the	 antibody	 to	 the	 membrane.	 Primary	 antibodies	 were	 added	 to	 the	
membrane	 as	 in	 Table	 2.1,	 and	 incubated	 overnight	 at	 4°C	 with	 shaking.	 Non-specific	
primary	 antibody	 was	 removed	 with	 three	 10	 minute	 washes	 in	 TBST,	 with	 shaking.	
Secondary	 antibody	was	 added	 to	 the	membrane	 as	 in	 Table	 2.1,	 and	 incubated	 for	 1	





Protein	 bands	 were	 detected	 using	 LumiGlo	 chemiluminescent	 substrate	 (KPL	 Inc.	
Gaithersburg,	MD,	USA).	The	substrate	was	added	to	the	nitrocellulose	membrane,	and	
converted	 by	 horseradish	 peroxidase	 (HRP),	 which	 is	 conjugated	 to	 the	 secondary	
antibody,	 to	 a	 luminescent	 product.	 Luminescent	 protein	 bands	 were	 detected	 by	
exposing	 X-ray	 film	 (AGFA	 CU-BP	 Medical	 X-ray	 film,	 Mostel,	 Belgium),	 for	 varying	























with	0.25%	Triton-X-100	 in	PBS	 for	5	minutes	at	 room	temperature.	After	one	wash	 in	
PBST,	 the	 cells	were	 blocked	 using	 1%	 BSA	 in	 PBST	 +	 0.3	M	 glycine	 for	 30	minutes	 at	




in	 PBS)	 for	 5	 minutes	 to	 stain	 for	 nuclear	 DNA,	 before	 washing	 once	 with	 PBS.	 The	
coverslips	were	then	mounted	onto	glass	slides	using	Mowiol	or	Vectashield,	and	images	
were	 visualised	 using	 a	 Zeiss	 Inverted	 Fluorescence	Microscope	 or	 a	 Nikon	 Eclipse	 90i	
microscope,	under	100	x	oil	 immersion.	 Images	were	captured	using	the	AxioVision	4.7	




























































Cells	were	prepared	similarly	to	that	 for	 immunofluorescence.	After	 fixation,	cells	were	
washed	 twice	 in	0.04%	PBST	and	blocked	 in	1%	BSA	 for	30	minutes.	Actin	was	 labeled	
with	 50	 ng/ml	 Phalloidin-Tetramethylrodamine	 B	 isothiocyanate	 (Phalloidin)	 (Sigma-
Aldrich,	St	Louis,	MO,	USA)	in	1%	BSA	for	30	minutes	at	room	temperature.	After	washing	
twice	with	PBS,	 cell	nuclei	were	 stained	with	100	ng/ml	DAPI	 in	PBS	 for	10	minutes	at	
room	 temperature.	 The	 stained	 cells	were	 then	washed	 twice	 in	 PBS	 and	mounted	on	
slides	using	Mowiol.	Phalloidin	images	were	viewed	using	the	Zeiss	Inverted	Fluorescence	




























microplate	 spectrophotometer	 (Winooski,	 VT,	 USA).	 A	 higher	 absorbance	 reading	
	 36	
correlates	with	a	larger	number	of	viable	cells.	Briefly,	cells	were	plated	in	96	well	plates	
and	 allowed	 to	 proliferate	 for	 a	 period	 of	 3	 or	 4	 days,	 during	which	 viable	 cells	 were	
measured	 by	 addition	 of	 the	MTT	 reagent	 (Cell	 Proliferation	 Kit	 I,	 Roche,	 Mannheim,	
Germany)	 for	 4	 hours	 followed	 by	 solubilisation	 solution,	 at	 37°C.	 The	 following	 day,	







methacrylate)	 (Poly-HEMA)	 (Sigma-Aldrich,	 St	 Louis,	 MO,	 USA)	 coated	 96-well	 plates.	
Each	well	of	the	96-well	plate	was	coated	with	30	μl	of	12	mg/ml	Poly-HEMA	and	left	to	
dry	 overnight	 in	 the	 tissue	 culture	 hood	 under	 UV	 light.	 HeLa	 and	 CaSki	 cells	 (10	 000	
cells/well)	were	 resuspended	 in	 1%	methyl	 cellulose-containing	media	 and	 plated	 into	
the	 poly-HEMA	 coated	wells.	 The	 increased	 density	 of	 the	methyl	 cellulose-containing	
media	 ensures	 that	 individual	 cells	 don’t	 adhere	 to	 each	 other,	 so	 that	 the	 ability	 of	












with	0.4%	Trypan	Blue	 (Merck	Millipore,	Billerica,	MA,	USA),	which	 is	 taken	up	by	non-
viable/dead	cells	 thereby	 staining	 them	blue.	Viable	 (white)	 and	non-viable	 (blue)	 cells	







well	 plate	 and	 allowed	 to	 settle	 overnight.	 The	 following	 day,	 cells	 were	 treated	with	
varying	concentrations	of	the	appropriate	drug	for	a	period	of	48	hours,	after	which	MTT	
and	 solubilisation	 solution	 were	 added	 as	 previously	 described.	 The	 following	 day,	












using	 8	ml	 ice-cold	 100%	ethanol.	 Cells	 in	 ethanol	were	 stored	 at	 -20°C	 for	 up	 to	 two	
weeks.	 In	 preparation	 for	 FACS	 analysis,	 ethanol	 was	 removed	 from	 cells	 by	
centrifugation,	and	0.5x106	cells	were	transferred	to	a	sterile	eppendorf	tube.	RNA	was	
removed	 by	 incubating	 cells	 with	 50	 μg/ml	 RNase	 in	 PBS	 for	 30	minutes.	 20	minutes	
before	analysis	the	cellular	DNA	was	stained	using	a	stain	solution	containing	propidium	
iodide	 (see	 Appendix	 I)	 and	 cell	 cycle	 profiles	 were	 analysed	 using	 the	 Accuri	 Flow	






















and	 left	 to	adhere	overnight.	The	 following	day	cells	were	 transfected	with	50	ng	GFP-
NFAT	(Addgene	plasmid	#24219;	gift	of	Jerry	Crabtree88),	50	ng	NFAT-luciferase	(Addgene	
plasmid	 #10959;	 gift	 of	 Toren	 Finkel89),	 and	 5ng	 pRL-TK	 (encoding	 Renilla	 luciferase;	




Luciferase	 activity	 was	 assayed	 using	 the	 Dual-Luciferase	 Reporter	 assay	 system	
(Promega)	 according	 to	 the	 manufacturers	 instructions.	 Luciferase	 readings	 measured	






For	 half-life	 determination	 experiments,	 cells	 were	 pretreated	with	 5	µM	 INI-43	 for	 3	
hours	before	treatment	with	40	μg/ml	cycloheximide	(CHX)	(Sigma-Aldrich,	St	Louis,	MO,	
USA).	Protein	was	harvested	at	various	time	points	after	CHX	treatment	and	quantitated	
using	 the	 BCA	 protein	 assay	 as	 previously	 described.	 20	 μg	 of	 each	 cell	 lysate	 was	
subjected	 to	 Western	 blot	 analysis	 and	 probed	 with	 anti-Kpnβ1,	 Kpnα2	 and	 CRM1	
antibodies.	 GAPDH	 was	 used	 a	 control	 for	 loading.	 Protein	 bands	 were	 subsequently	
quantitated	 by	 densitometric	 scanning	 using	 the	 ImageJ	 analysis	 software	 (NIH,	
	 40	
Bathesda,	MD,	USA),	and	normalised	to	GAPDH.	In	order	to	determine	protein	half-life,	
the	 band	 intensities	 were	 plotted	 in	 log	 scale	 relative	 to	 time,	 and	 a	 linear	 trendline	







with	 dysregulated	 Kpnβ1	 levels	 (ie.	 Inducible	 Kpnβ1	 overexpression	 and/or	 INI-43	
mediated	 inhibition).	HeLa	TET	ON	Kpnβ1-GFP	cells	were	 seeded	 in	8-well	micro	 slides	
(ibiTreat,	 code	 80826,	 Ibidi,	 Klopferspitz,	 Martinsried,	 Germany),	 and	 subjected	 to	
various	 treatments	with	 doxycycline	 (Sigma-Aldrich,	 St	 Louis,	MO,	 USA)	 and/or	 INI-43.	
Just	 prior	 to	 recording,	 cell	media	was	 replaced	with	 TET-free	 DMEM	 (no	 phenol	 red)	
(Thermo	Fischer	Scientific,	MA,	USA)	supplemented	with	0.5	µg/ml	doxycycline	to	allow	
for	the	continuous	stimulation	of	the	cells.	Cells	were	analysed	for	a	period	of	24	hours	
using	 an	 Eclipse	 Ti	 inverted	 microscope	 (Nikon,	 Minato,	 Tokyo,	 Japan)	 and	 a	 60	 x	
objective	(Plan	Apo,	1.4	N.A.		Differential	Interference	Contrast	(DIC),	Nikon).	During	the	










standard	 error	 of	 the	 mean	 (SEM),	 unless	 otherwise	 stated.	 All	 experiments	 were	
performed	 at	 least	 two	 independent	 times.	 For	 data	 analysis,	 the	 Student's	 t-test	was	











The	 identification	 and	 further	 characterisation	 of	 Kpnβ1	 as	 a	 potential	 anti-cancer	




apoptosis14,	 and	Kuusisto	and	 Jans	 (2015)	 recently	 showed	using	protein	knockdown	
studies	 that	 faster	 growing	 tumour	 cells	 expressing	 high	 levels	 of	 Kpnβ1	 are	 more	
dependent	 on,	 or	 “addicted	 to”,	 Kpnβ1	 than	 their	 non-transformed	 counterparts73.		
These	results	demonstrate	that	increased	expression,	and	thus	activity,	of	Kpnβ1	likely	




study	protein	 function	 in	 vitro,	by	 investigating	 the	biological	effects	associated	with	
altered	 expression.	 Previous	 studies	 in	 our	 laboratory	 revealed	 that	 siRNA-mediated	
knockdown	 of	 Kpnβ1	 lead	 to	 a	 reduction	 in	 proliferation	 of	 cancer	 cells	 and	
	 43	
subsequent	increase	in	apoptosis,	while	normal	cells	were	relatively	unaffected14,90.	It	
is	 possible	 that	 cancer	 cells	 have	devised	 a	mechanism	 to	 cope	with	 their	 increased	











by	 specifically	 studying	 the	 biological	 effects	 associated	with	 Kpnβ1	 overexpression.	
This	study	includes	investigating	the	effects	of	stable	expression	of	exogenous	Kpnβ1	
in	 cervical	 cancer	 cells	 (HeLa	 and	 CaSki),	 as	 well	 as	 the	 effects	 of	 transient	
overexpression	 of	 Kpnβ1	 in	 non-cancer	 cells.	 In	 addition	 to	 previously	 published	
research	 verifying	 the	 importance	 of	 Kpnβ1	 in	 a	 variety	 of	 biological	 processes,	 our	












for	 overexpression	 of	 Kpnβ1	 (pEFIRES-Kpnβ1-EGFP;	 Figure	 3.1	 A)	 was	 generated	 by	
inserting	 SacI-	 and	 NotI-digested	 human	 Kpnβ1-EGFP,	 released	 from	 the	 plasmid	
pEGFP-Kpnβ1	 (kind	 gift	 from	 Patrizia	 Lavia,	 Institute	 of	 Molecular	 Biology	 and	
Pathology,	National	Research	Council	of	Italy,	Rome,	Italy)87,	into	the	pEFIRES	plasmid	
(kind	 gift	 from	 Yosef	 Shaul,	 Weizmann	 Institute	 of	 Science,	 Israel)86.	 The	 pEFIRES	
plasmid	 was	 used	 in	 order	 to	 allow	 for	 both	 the	 Kpnβ1-EGFP	 fusion	 gene	 and	 the	
puromycin	resistance	gene	to	be	transcribed	as	a	single	mRNA	transcript.	The	presence	
of	an	 internal	 ribosome	entry	 site	 (IRES)	upstream	of	 the	puromycin	 resistance	gene	
ensures	 that	 puromycin-resistant	 clones	 express	 high	 levels	 of	 the	 recombinant	
protein,	 Kpnβ1-EGFP.	 pEFIRES-EGFP	 was	 used	 as	 a	 control.	 Positive	 clones	 were	








To	 confirm	 the	 presence	 of	 EGFP	 and	 Kpnβ1-EGFP,	 cells	 were	 visualised	 using	
fluorescence	microscopy.	HeLa	and	CaSki	cells	expressing	pEFIRES-EGFP	(referred	to	as	
EGFP)	showed	nuclear	and	cytoplasmic	fluorescence,	due	to	the	fact	that	EGFP	is	small	
(~32kDa)	 and	 can	 thus	 passively	 diffuse	 across	 the	 NPC.	 HeLa	 and	 CaSki	 cells	
expressing	 pEFIRES-Kpnβ1-EGFP	 (referred	 to	 as	 Kpnβ1-EGFP)	 show	 nuclear	 and	
cytoplasmic	 localisation	 of	 exogenous	 Kpnβ1,	 as	 well	 as	 a	 distinct	 perinuclear	 band	
(Figure	3.2	A).	This	makes	sense,	as	the	localisation	of	Kpnβ1	is	related	to	its	function;	
in	 interphase	cells	Kpnβ1	acts	as	a	nuclear	 import	protein	and	 is	 thus	present	 in	 the	
nucleus	and	cytoplasm,	as	well	as	around	the	nuclear	envelope,	due	to	its	association	
with	nuclear	pores.	Western	blot	analysis	of	protein	lysates	harvested	from	EGFP	and	
Kpnβ1-EGFP	 cells	 revealed	 that	 Kpnβ1-EGFP	 was	 expressed	 at	 roughly	 equivalent	
levels	to	that	of	endogenous	Kpnβ1	in	both	HeLa	and	CaSki	cells	(Figure	3.2	B).		






































Kpnβ1-EGFP	 construct	 used	 for	 creation	 of	 HeLa	 and	 CaSki	 stable	 cell	 lines	 stably	
overexpressing	Kpnβ1,	into	which	the	2631	bp	Kpnβ1-encoding	fragment	attached	to	a	
EGFP	protein	was	cloned	within	the	MCS	of	the	pEFIRES	vector.	The	Kpnβ1-EGFP	fusion	
protein	 is	 under	 control	 of	 the	 human	 elongation	 factor	 1α	 promoter	 (pEF-1α).												
B:	Restriction	enzyme	digest	of	the	pEFIRES-Kpnβ1-EGFP	plasmid	using	the	restriction	
enzymes	SacI	and	BamHI.	Digestion	products	were	electrophoresed	on	a	1%	agarose	
































































Figure	 3.2.	 Stable	 expression	 of	 EGFP	 and	 Kpnβ1-EGFP	 in	 HeLa	 and	 CaSki	 cells.											


























































To	 determine	 the	 effect	 of	 Kpnβ1	 overexpression	 on	 anchorage-dependent	 cell	
proliferation,	 cell	 viability	 assays	were	 performed	 and	 live	 cells	 scored	 using	 Trypan	
Blue.	Results	revealed	that	overexpression	of	Kpnβ1	results	in	a	significant	reduction	in	
the	proliferation	 (or	 viability)	 of	 adherent	HeLa	 and	CaSki	 cells	 (Figure	 3.3	A	 and	B).	
When	the	effect	of	Kpnβ1	overexpression	on	cell	proliferation	was	expanded	to	look	at	
cells	grown	under	anchorage-independent	conditions	using	methyl	cellulose,	a	similar	
result	 was	 observed;	 a	 significant	 reduction	 in	 proliferation	 of	 HeLa	 and	 CaSki	 cells	
stably	expressing	Kpnβ1-EGFP	 (Figure	3.4	A	and	B).	 This	 suggests	 that	Kpnβ1	plays	a	
role	in	cell	proliferation,	however	expression	of	exogenous	Kpnβ1	(over	and	above	the	
levels	already	present	in	cancer	cells)	does	not	appear	to	provide	a	growth	advantage	
in	 either	 adherent	 or	 non-adherent	 conditions.	 Rather,	 overexpression	 of	 Kpnβ1	
results	 in	 a	 growth	 disadvantage,	 likely	 due	 to	 an	 imbalance	 in	 Kpnβ1-mediated	
processes	 such	 as	 nuclear	 import	 and	 mitotic	 progression.	 Interestingly,	 Kpnβ1	









Figure	 3.3.	 Stable	 overexpression	 of	 Kpnβ1	 results	 in	 a	 reduction	 in	 anchorage-
dependent	 proliferation	 of	 HeLa	 and	 CaSki	 cells.	 Trypan	 Blue	 assays	 revealed	 a	
significant	 reduction	 in	 the	 number	 of	 live	 HeLa	 (A)	 and	 CaSki	 (B)	 cells	 expressing	
Kpnβ1-EGFP	compared	to	EGFP.	Cells	were	counted	for	a	period	of	up	to	4	days	post	


























































Figure	 3.4.	 Stable	 overexpression	 of	 Kpnβ1	 results	 in	 a	 reduction	 in	 anchorage-
independent	proliferation	of	HeLa	and	CaSki	cells.	MTT	cell	proliferation	assays	reveal	
a	 significant	 reduction	 in	 the	 anchorage-independent	 proliferation	 of	 HeLa	 (A)	 and	
CaSki	 (B)	 cells	 stably	 overexpressing	 Kpnβ1.	 Cells	 growing	 adherently	were	 plated	 in	

























































To	 investigate	 the	 effects	 of	 Kpnβ1	 overexpression	 on	 cell	 cycle	 progression,	
Fluorescence-activated	 cell	 sorting	 (FACS)	 analysis	 was	 performed	 to	 quantify	
percentage	of	 cells	 in	each	phase	of	 the	 cell	 cycle.	Asynchronous	 cells	 revealed	only	
minor	changes	when	Kpnβ1	was	overexpressed	(data	not	shown),	thus	HeLa	EGFP	and	
Kpnβ1-EGFP	cells	were	synchronised	to	late	G1/early	S	phase	using	a	thymidine	block	
and	harvested	at	 0,	 2,	 4,	 6,	 8,	 10	and	24	hours	post	 release	 into	 complete	medium.	
FACS	analysis	of	 synchronised	cells	 revealed	 that	Kpnβ1	overexpression	resulted	 in	a	
prolonged	delay	or	progression	 from	the	G1/S	block,	as	Kpnβ1-EGFP	expressing	cells	
progressed	 through	 the	 cell	 cycle	 much	 slower	 than	 the	 control	 EGFP	 cells												
(Figure	3.5	A).	Quantification	of	the	percentage	of	HeLa	EGFP	and	Kpnβ1-EGFP	cells	in	
each	 phase	 of	 the	 cell	 cycle	 showed	 that	 while	 50%	 of	 control	 cells	 had	 exited	 G1	
phase	and	entered	S	phase	by	approximately	3	hours,	it	took	approximately	6	hours	for	
the	Kpnβ1-EGFP	cells	to	reach	the	same	stage	(see	arrows;	Figure	3.5	B	and	C).	These	











during	 S	 and	G2	 phase	 and	 peak	 at	mitosis91,	 and	 this	 same	 trend	was	 observed	 in	
EGFP	 cells.	 Kpnβ1-EGFP	 cells,	 however,	 showed	 a	 decrease	 in	 expression	 from	 the	
baseline	 levels	 observed	 in	 asynchronous	 cells,	 suggesting	 that	 Mcl-1	 may	 be	




CaSki	 EGFP	 and	 Kpnβ1-EGFP	 cells	 harvested	 at	 various	 time-points	 post	 thymidine	
release	were	also	analysed	for	changes	in	expression	of	cell	cycle-associated	markers.	
While	 not	 as	 pronounced	 as	 that	 observed	 in	 HeLa	 cells,	 CaSki	 cells	 overexpressing	
Kpnβ1	revealed	a	slight	delay	in	progression	through	the	cell	cycle	from	the	thymidine	
block.	Expression	of	pHisH3	at	10	hours	post	release	was	reduced	in	Kpnβ1-EGFP	cells	
compared	 to	EGFP	 cells,	 indicating	 that	 fewer	 cells	had	 reached	mitosis	by	10	hours	
(Figure	 3.6	 B).	 A	 decrease	 in	 expression	 of	 Mcl-1	 was	 also	 observed	 in	 CaSki	 cells	
overexpressing	 Kpnβ1.	 These	 results	 suggest	 that	 CaSki	 cells	 overexpressing	 Kpnβ1,	















released	 into	 complete	 medium,	 harvested	 at	 0,	 2,	 4,	 6,	 8,	 10	 and	 24	 hours	 after	
release,	and	stained	with	propidium	iodide	(PI)	to	monitor	their	cell	cycle	distribution.	
An	asynchronous	culture	of	cells	(async.)	was	used	for	comparison.	Representative	cell	
cycle	 profiles	 from	 data	 acquired	 using	 the	 BD	 Accuri	 Flow	 Cytometer	 from	
experiments	performed	in	triplicate	and	repeated	three	times	are	shown.	B	and	C:	Line	






























































	 	 	 	G1	 G2/M	 G1	 G2/M	
	 54	
Figure	 3.6.	 Kpnβ1	 overexpression	 results	 in	 changes	 in	 expression	 of	 cell	 cycle	
associated	 proteins.	 A:	Western	 blot	 analysis	 was	 used	 to	 determine	 the	 expression	
levels	of	various	cell	cycle	associated	proteins	at	0,	2,	4,	6,	8,	10	and	24	hours	post	release	
following	 thymidine	 synchronisation,	 in	 HeLa	 EGFP	 and	 Kpnβ1-EGFP	 cells.	 Protein	
harvested	from	an	asynchronous	culture	of	cells	(a)	is	shown	for	comparison.	GAPDH	was	
used	 as	 a	 control	 for	 loading.	 Representative	 data	 from	 experiments	 performed	 three	
independent	 times	 is	 shown.	 B:	 CaSki	 EGFP	 and	 Kpnβ1-EGFP	 cells	 were	 similarly	
harvested	 at	 0,	 4	 and	 10	 hours	 after	 release	 following	 thymidine	 synchronisation,	 and	








































HeLa	 and	 CaSki	 cells	 stably	 overexpressing	 Kpnβ1	 showed	 distinct	 changes	 in	 cell	




morphology;	 due	 to	 the	 vital	 role	 that	 it	 plays	 in	multiple	 cellular	 processes,	 during	
both	 interphase	 and	mitosis,	 it	 is	 likely	 that	 Kpnβ1	 dysregulation	 has	 an	 impact	 on	
many	cellular	phenotypes	or	events.		
	
Changes	 in	 cell	morphology	 are	 often	 driven	 by	 rearrangement	 of	 the	 cytoskeleton;	
thus	we	next	investigated	whether	the	morphological	changes	associated	with	Kpnβ1	
overexpression	 were	 linked	 to	 changes	 in	 actin	 redistribution.	 Immunofluorescence	
actin	staining	assays	were	performed	using	phalloidin,	a	high-affinity	filamentous	actin	
(F-actin)	 probe,	 to	 investigate	 actin	 reorganisation	 in	 HeLa	 and	 CaSki	 cells	 stably	
overexpressing	Kpnβ1.	Phalloidin	staining	revealed	changes	in	cell	shape,	as	well	as	a	
reduction	in	the	number	of	actin-rich	cytoplasmic	extensions	seen	at	the	edges	of	the	
elongated,	 spindle-shaped	 control	 cells,	 more	 evident	 in	 HeLa	 cells	 (Figure	 3.8	 A).	
Quantification	 of	 these	 results	 showed	 that	 Kpnβ1	 overexpression	 resulted	 in	 a	




































































cells.	 A:	 Fluorescent	 staining	 of	 polymeric	 F-actin	 using	 phalloidin	 (red)	 in	 EGFP	 and	
Kpnβ1-EGFP	 expressing	 cells.	 DAPI	 stain	was	 used	 to	 visualise	 the	 cell	 nuclei	 (blue).						
B	 and	 C:	 Quantification	 of	 the	 changes	 in	HeLa	 (B)	 and	 CaSki	 (C)	 cell	 area	 from	 the	
captured	 fluorescent	 images.	 Cell	 area	 was	 calculated	 using	 the	 AxioVision	 4.7	




























































cells	 suggests	 that	 overexpression	 of	 Kpnβ1	 causes	 cells	 to	 pack	 tighter	 and	 form	
clusters,	which	 indicates	 the	possibility	of	 tight	 junction	 formation	and	 increased	cell	
adhesion.	 Thus,	 to	 investigate	 whether	 the	 observed	 morphological	 changes	 were	
associated	 with	 any	 changes	 in	 cell	 adhesion,	 adhesion	 assays	 were	 performed.	
Adhesion	 assays	 using	 uncoated	 cell	 culture	 dishes	 were	 used	 to	 determine	 overall	
changes	 in	 the	 adhesion	 properties	 of	 cells	 (particularly	 those	 involving	 cell-
surface/cell-substrate	 interactions).	 Results	 show	 that	 HeLa	 and	 CaSki	 cells	
overexpressing	 Kpnβ1	 were	 significantly	 more	 adherent	 compared	 to	 control	 cells	
(Figure	3.9	A	and	B).	Furthermore,	the	expression	levels	of	various	proteins	shown	in	
the	literature	to	be	involved	in	adhesion,	such	as	E-cadherin	(plays	an	important	role	in	
promoting	 cell-cell	 adhesion93),	 and	 Vimentin	 (a	 marker	 of	 mesenchymally	 derived,	
non-adherent	 cells94),	 were	 also	 investigated.	 	 Western	 blot	 analysis	 revealed	 that						
E-cadherin	 levels	were	elevated	 in	HeLa	and	CaSki	 cells	overexpressing	Kpnβ1,	while	
Vimentin	 levels	 were	 decreased	 (Figure	 3.9	 C	 and	 D).	 These	 results	 suggest	 that	






Figure	 3.9.	 Overexpression	 of	 Kpnβ1	 results	 in	 changes	 in	 the	 adhesion	 and	
expression	 of	 cell	 adhesion	markers	 in	 HeLa	 and	 CaSki	 cells.	 A	 and	 B:	 Relative	 cell	
adhesion	in	control	and	Kpnβ1-EGFP	HeLa	(A)	and	CaSki	(B)	cells.	Adherent	cells	were	
fixed	 (after	 removing	 non-adherent	 cells	 by	 washing)	 and	 stained	 with	 0.5%	 crystal	
violet	solution.	Cells	over	ten	fields	of	view	were	counted	using	ImageJ	and	normalised	
to	 unwashed	 cells.	 Results	 shown	 represent	 the	 mean	 ±	 SEM	 for	 experiments	
performed	in	triplicate	and	repeated	at	least	two	independent	times	(*p	<	0.05).	C	and	






































































































Various	studies	have	revealed	that	a	precise	balance	of	Kpnβ1	to	Ran	 is	 required	 for	
correct	mitotic	functioning,	and	have	suggested	that	if	one	factor	is	overexpressed	(ie.	
Kpnβ1),	upregulation	of	 the	other	 (ie.	Ran)	 should	 restore	 the	balance	and	allow	 for	
rescue	 of	 the	 impaired	 functioning	 associated	 with	 overexpression	 of	 either	 factor	
alone68,87,95.	We	therefore	hypothesised	that	the	reduction	in	cancer	cell	proliferation	
associated	 with	 overexpression	 of	 Kpnβ1	 could	 be	 rescued	 by	 the	 expression	 of	
exogenous	 Ran.	 Thus,	 in	 order	 to	 investigate	 the	 effects	 associated	 with	
overexpression	 of	 Ran,	 both	 in	 the	 absence	 and	 presence	 of	 stable	 Kpnβ1	
overexpression,	HeLa	EGFP	and	Kpnβ1-EGFP	cells	were	transfected	with	plasmid	DNA	
containing	 Ran-EGFP	 and	 expression	 was	 confirmed	 by	 western	 blot	 analysis							
(Figure	3.10	A).	Anchorage-dependent	MTT	proliferation	assays	 revealed	 that	 similar	
to	what	was	seen	with	Kpnβ1	overexpression,	Ran	overexpression	resulted	in	a	small	
but	significant	reduction	in	the	proliferation	of	HeLa	cells	(Figure	3.10	B).	Interestingly,	
when	 Ran-EGFP	 was	 expressed	 in	 cells	 already	 stably	 expressing	 Kpnβ1-EGFP	 there	
was	 a	 further	 reduction	 in	 proliferation,	 greater	 than	 that	 observed	 with	
overexpression	 of	 either	 Kpnβ1	 or	 Ran	 alone.	 These	 results	 suggest	 that	 cells	 are	
particularly	unable	to	cope	with	an	imbalance	in	the	levels	of	Kpnβ1	and	Ran,	factors	







expression	 levels	 at	 24	 hours	 post	 transfection	 of	 HeLa	 EGFP	 and	 Kpnβ1-EGFP	 cells	
with	pEGFP-C2	and	Ran-EGFP	plasmids.	First	lane	(untx)	represents	protein	harvested	
from	 untransfected	 cells.	 GAPDH	 was	 used	 as	 a	 control	 for	 loading.	 B:	 MTT	
proliferation	assays	show	a	significant	reduction	in	the	proliferation	of	HeLa	EGFP	cells	
transiently	 expressing	 Ran-EGFP.	 Expression	 of	 Ran-EGFP	 in	 cells	 already	 stably	
expressing	 Kpnβ1-EGFP	 results	 in	 a	 further	 reduction	 in	 proliferation.	 Results	 shown	
represent	 the	mean	 ±	 SEM	 for	 experiments	 performed	 in	 triplicate	 and	 repeated	 at	

















































































In	 order	 to	 investigate	 the	 effects	 of	 Kpnβ1	 overexpression	 on	 non-cancer	 cell	
proliferation,	 establishment	 of	 a	 cell	 line	 stably	 expressing	 Kpnβ1-EGFP	 was	
attempted.	 Despite	 optimisation	 of	 transfection	 conditions	 using	 various	 cell	 lines,	
transfection	 reagents,	 plasmid	 backbones,	 and	 amount	 of	 plasmid	 DNA	 transfected,	
generation	of	a	non-cancer	stable	cell	 line	was	unsuccessful.	As	a	 result,	FG0	normal	





(suggesting	adequate	 transfection	efficiency),	 levels	of	Kpnβ1-EGFP	were	very	 low	 in	
cells	 transfected	 with	 the	 equivalent	 amount	 of	 pEFIRES-Kpnβ1-EGFP	 (after	 much	
optimisation	of	 transfection	conditions,	 levels	of	Kpnβ1-EGFP	could	not	be	 improved	
upon)	(Figure	3.11	A).		
	
MTT	 proliferation	 assays	 revealed	 that	 FG0	 cells	 expressing	 Kpnβ1-EGFP	 showed	 a	
marginal	but	 significant	 reduction	 in	proliferation	compared	 to	cells	expressing	EGFP	
(Figure	 3.11	B).	 It	 is	 possible	 that	 cells	 transfect	 less	 efficiently	with	 pEFIRES-Kpnβ1-
EGFP	than	pEFIRES-EGFP	due	to	the	plasmids	large	size	(it	contains	the	2631bp	Kpnβ1-
encoding	fragment),	but	that	even	low	levels	of	Kpnβ1	overexpression	are	sufficient	to	
result	 in	 a	 decrease	 in	 the	 proliferation	 of	 FG0	 cells.	 However,	 given	 the	 poor	
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expression	of	 Kpnβ1-EGFP	 in	 these	 cells	 it	 cannot	 be	 reasonably	 concluded	 that	 the	









B:	 MTT	 proliferation	 assays	 revealed	 a	 small	 but	 significant	 reduction	 in	 the	

































































Changes	 in	 gene	 expression	 patterns	 are	 a	 significant	 driver	 of	 cancer	 progression.	
Thus,	 the	 identification	 of	 genes	 and	 pathways	 involved	 in	 and/or	 altered	 in	 this	
process	will	not	only	improve	our	understanding	of	cancer	initiation	and	development,	
but	will	also	provide	evidence	for	the	identification	of	novel	anti-cancer	drug	targets.	
Previous	 studies	 have	 revealed	 Karyopherin	β1	 (Kpnβ1),	 the	 primary	 nuclear	 import	
protein,	 to	 be	 significantly	 overexpressed	 in	 a	 variety	 of	 cancer	 types	 including	
cervical14,	 gastric76,	 and	 breast	 cancers73.	 Furthermore,	 these	 studies	 reveal	 that	
inhibition	 of	 Kpnβ1	 expression	 leads	 to	 cancer	 cell	 death,	while	 van	 der	Watt	et	 al.	
(2009)	showed	that	inhibition	of	Kpnβ1	protein	expression	in	non-cancer	cells	has	only	
a	minor	effect	on	cell	viability14.	These	results	suggest	that	Kpnβ1	has	potential	as	an	
anti-cancer	 therapeutic	 target,	 thus	warranting	 further	 research	 into	 the	 association	
between	Kpnβ1	expression	and	cancer	progression.	
	
Of	 particular	 interest	 in	 this	 study	 is	 the	 role	 that	 Kpnβ1	 plays	 in	 various	 processes	
associated	 with	 cellular	 transformation	 and	 cancer	 progression.	 When	 validating	 a	
protein	as	an	anti-cancer	target,	 identifying	whether	the	protein	 is	 in	 fact	a	driver	of	
cancer,	or	certain	cancer	phenotypes,	is	crucial	(i.e.	is	it	able	to	induce	features	of	the	
transformed	or	cancer	phenotype?).	While	 the	potential	 for	Kpnβ1	as	an	anti-cancer	
target	 has	 been	 validated	 by	 protein	 knockdown	 studies	 in	 various	 normal,	
transformed	and	cancer	cell	lines,	research	into	the	role	that	Kpnβ1	plays	in	malignant	
transformation	 and	 tumour	 progression	 remains	 limited.	 The	 aim	 of	 this	 study	 was	
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cell	 lines	 were	 investigated.	 Through	 the	 use	 of	 a	 GFP-tagged	 expression	 vector	
system,	 stable	 Kpnβ1	 overexpressing	 cell	 lines,	 HeLa	 and	 CaSki	 pEFIRES-Kpnβ1-EGFP	
were	created,	and	the	effects	on	various	biological	processes	such	as	cell	proliferation,	
cell	cycle,	cell	morphology	and	adhesion	were	observed.	In	order	to	study	the	effects	






not	 normal	 cells,	 suggesting	 that	 increased	 levels	 of	 Kpnβ1	 are	 likely	 essential	 to	
cancer	 cell	 biology14.	 Our	 findings	 described	 in	 this	 study	 show	 that	 stable	




The	 reduction	 in	 proliferative	 rate	 and	 delay	 in	 cell	 cycle	 progression	 as	 a	 result	 of	









why	 disruption	 of	 Kpnβ1	 expression	 in	 cervical	 cancer	 cells	 (by	 inhibition	 or	
overexpression)	 has	 detrimental	 effects	 on	 cancer	 cell	 proliferation	 and	 cell	 cycle	
progression.	 In	 this	 study,	 we	were	 unable	 to	 achieve	 successful	 synchronisation	 of	
cells	 to	 mitosis,	 but	 we	 hypothesise	 that	 Kpnβ1	 overexpression	 would	 result	 in	 a	




import.	 For	 example,	 a	 recent	 review	 shows	 how	 the	 Karyopherin	 proteins	 are	
involved	 in	 controlling	 a	 large	 number	 of	 epithelial-mesenchymal	 transition	 (EMT)	
promoting	 pathways97.	 Kpnβ1	 has	 been	 shown	 to	 be	 involved	 in	 the	 nuclear	
translocation	 of	 a	 number	 of	 EMT-promoting	 proteins	 including	 Snail98,	 Smad99,	 and	
Notch100,	all	of	which	play	a	role	 in	 increasing	cancer	cell	 invasion	and	metastasis.	 In	
addition	 to	 this,	 Kpnβ1	 has	 also	 been	 shown	 to	 play	 a	 role	 in	 actin	 cytoskeleton	
regulation,	by	regulating	the	interaction	between	an	actin	binding	kinesin	(NabKin)	and	
F-actin,	 demonstrating	 that	 Kpnβ1	 likely	 plays	 a	 role	 in	 influencing	 cytoskeletal	
elements	and	structure68,69.	We	showed	that	Kpnβ1	overexpression	in	HeLa	and	CaSki	
cells	 results	 in	 changes	 in	 cell	 morphology	 and	 actin	 reorganisation,	 with	 cells	
becoming	 smaller	 and	 more	 epithelial-like.	 	 In	 addition,	 Kpnβ1	 overexpressing	 cells	
	 68	
showed	 enhanced	 adhesion,	 as	 well	 as	 an	 increase	 in	 E-cadherin	 and	 decrease	 in	
Vimentin	protein	expression.	These	results	suggest	that	overexpression	of	Kpnβ1	does	
not	enhance	the	EMT	process,	but	rather	results	in	a	reversed	EMT,	or	mesenchymal-
epithelial	 transition	 (MET),	 where	 cells	 transition	 from	motile,	 more	 spindle-shaped	
mesenchymal	 cells	 to	 adherent,	 more	 compact/columnar	 epithelial	 cells.	 There	 is	
much	 evidence	 linking	 the	 EMT	 process	 with	 tumour	 progression	 and	 malignant	
transformation,	as	transitioning	to	a	more	mesenchymal	state	promotes	cell	 invasion	
and	metastasis	 (or	cancer	cell	dissemination)101.	More	recently,	evidence	has	started	
to	 emerge	 supporting	 the	 concept	 that	 MET	 may	 be	 important	 for	 metastatic	
colonisation,	 but	 research	 remains	 limited.	 Thus,	 it	 appears	 as	 if	 overexpression	 of	
Kpnβ1	 has	 negative	 consequences	 for	 the	 proliferation,	 progression	 and	 metastatic	
potential	of	cancer	cells.	
	
While	 Kpnβ1	 overexpression	 alone	 appears	 to	 be	 insufficient	 to	 induce	 any	 of	 the	




cycle.	 In	 interphase	 cells,	 Ran	 is	 responsible	 for	 providing	 energy	 and	 determining	
directionality	 of	 transport	 and	 without	 it	 nucleo-cytoplasmic	 shuttling	 would	 be	
dysfunctional.	In	mitotic	cells,	Ran	plays	an	important	role	in	counter-regulating	Kpnβ1	
activity22.	A	number	of	studies	have	revealed	that	a	precise	balance	of	Kpnβ1	to	Ran	is	
required	 for	 the	 correct	 functioning	 of	 various	 mitotic	 processes,	 such	 as	 spindle	
formation87	and	nuclear	envelope	and	pore	assembly68,95,	suggesting	that	if	one	factor	
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is	 overexpressed	 (ie.	 Kpnβ1),	 upregulation	 of	 the	 other	 (ie.	 Ran)	 should	 restore	 the	







control/regulation	 of	 all	 factors	 involved	 in	 nuclear	 transport	 (ie.	 a	 precise	 balance),	
results	in	further	cellular	dysfunction.	It	is	also	possible	that	wild	type	Ran,	which	can	
be	bound	by	GTP	or	GDP	depending	on	its	cellular	location102,	is	insufficient	to	restore	
function	 and	 a	 higher	 ratio	 of	 RanGTP	 (RanGTP	 is	 required	 for	 the	 release	 of	 cargo	




While	 various	 studies	 have	 provided	 evidence	 to	 suggest	 that	 enhanced	 Kpnβ1	
expression	 is	 necessary	 for	 cancer	 cell	 survival	 and	 progression;	 van	 der	 Watt	 and	
colleagues	(2011)	showed	that	the	Kpnβ1	promoter	is	more	highly	active	in	cancer	and	
transformed	cells	compared	to	normal50,	and	Kuusisto	and	Jans	(2015)	recently	found	
that	malignant	 cell	 types	are	more	 sensitive	 to	Kpnβ1	protein	knockdown	 than	 their	
non-transformed	 counterparts	 implying	 that	 increased	 levels	 (or	 activity)	 of	 Kpnβ1	
likely	 plays	 a	 role	 in	 tumour	 progression73,	 no	 research	 has	 yet	 emerged	 to	 show	
whether	 Kpnβ1	 overexpression	 plays	 a	 role	 in	 the	 cellular	 transformation	 of	 non-
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cancer	 cells.	 The	 question	 remains	 as	 to	 whether	 overexpression	 of	 Kpnβ1	 alone	 is	
sufficient	 to	 induce/drive	cellular	 transformation?	A	number	of	 single	genes	 that	are	
able	 to	 induce	 cellular	 transformation	 due	 to	mutation	 and/or	 increased	 expression	
(i.e.	 proto-oncogenes)	 have	 been	 identified	 to	 date,	 including	 p53103,	 Ras104,	 and	
Myc105.	 Thus,	 to	 answer	 this	 question,	 we	 performed	 experiments	 in	 which	 Kpnβ1-
EGFP	was	transiently	expressed	in	FG0	normal	skin	fibroblasts.	Despite	only	achieving	
very	 low	levels	of	overexpression	in	our	experiments,	our	results	 indicate	that	Kpnβ1	
overexpression	resulted	 in	a	minor	 reduction	 in	 the	proliferation	of	non-cancer	cells,	
suggesting	that	Kpnβ1	alone	is	not	able	to	drive	cellular	transformation.	It	 is	possible	
that	 if	other	members	of	the	nuclear	transport	family	such	as	Kpnα2,	CRM1	and	Ran	
(all	 of	 which	 have	 been	 shown	 to	 be	 overexpressed	 in	 a	 variety	 of	 cancers15,106–108)	
were	also	upregulated,	enhanced	proliferation	and	other	effects	 associated	with	 the	
transformed	 phenotype	 may	 be	 seen.	 Interestingly,	 Ly	 and	 colleagues	 (2010)	
demonstrated	 that	 an	 activated	 Ran	 mutant	 (that	 displays	 5-fold	 greater	 levels	 of	
RanGTP	to	that	of	wild	type	Ran)	was	able	to	induce	the	cellular	transformation	of	NIH-
3T3	 fibroblasts	 and	 that	 the	 injection	 of	 these	 cells	 into	 mice	 resulted	 in	 tumour	
formation.	 They	 also	 discovered	 that	 increasing	 levels	 of	 active	 Ran	 triggers	 the	
activation	 of	 a	 variety	 of	 signaling	 proteins	 including	 EGFR,	 Ras	 and	 ERK,	 and	 that	
active	 Ran-induced	 cellular	 transformation	 was	 dependent	 on	 activated	 EGFRs109.	
These	lines	of	evidence	suggest	that	as	a	consequence	of	Ran	activation,	loss	of	growth	
factor	regulation	gives	rise	to	oncogenic	transformation	of	normal	cells.	This	 leads	to	










handle	 in	 terms	 of	 Kpnβ1	 expression	 levels,	 normal	 cells	 might	 require	 additional	
factors	 for	 oncogenic	 transformation.	 While	 it	 is	 known	 that	 Kpnβ1	 expression	 is	
















an	 effective	 target	 for	 the	 development	 of	 novel	 anti-cancer	 therapies.	 Thus,	 a	
structure-based	in	silico	screen	was	performed	to	identify	molecules	with	the	potential	
to	 bind	 Kpnβ1,	 and	 the	 Inhibitor	 of	 Nuclear	 Import-43	 (INI-43)	 was	 identified	 and	
further	examined	for	its	ability	to	block	Kpnβ1-mediated	nuclear	import	and	decrease	
cancer	 cell	 viability.	 Recently	 published	 data	 from	our	 laboratory	 reveals	 that	 INI-43	
significantly	 reduced	 the	proliferation	of	cancer	cells	and	 interfered	with	 the	nuclear	
localisation	of	Kpnβ1	and	known	Kpnβ1	cargo	proteins,	NFκB,	NFAT,	NFY	and	AP-152.	
Only	 a	 minimal	 effect	 was	 observed	 when	 treating	 normal	 cells	 with	 the	 same	





Validation	 of	 drug	 target	 specificity	 is	 an	 important	 step	 in	 drug	 discovery	 and	
development,	however	many	challenges	exist	and	countless	drug	candidates	 fail	due	
to	undesirable	side	effect	profiles	(partially	due	to	off-target	effects).	For	a	protein	to	
be	 a	 successful	 drug	 target	 it	 must	 be	 druggable,	 which	 essentially	 means	 that	 it	
should	 contain	 a	 binding	 site	 or	 region	 that	 favours	 interactions	 with	 small	
molecules110,111.	Such	a	binding	site	should	also	be	significantly	different	from	regions	
on	 similar	 (closely	 related)	 proteins,	 so	 as	 to	 reduce	 the	 possibility	 of	 off-target	
binding.	 For	 the	 identification	 of	 compounds	 with	 the	 potential	 to	 inhibit	 Kpnβ1,	 a	
rational	structure-based	approach	was	used	to	identify	small	molecules	that	bind	the	
overlapping	binding	region	of	Ran	and	Kpnα2	on	Kpnβ1.	This	region,	spanning	amino	




While	 the	 initial	 computational	 screen	 and	 subsequent	 research	 conducted	 in	 the	
laboratory	 suggest	 that	 INI-43	 functions	 by	 targeting	 Kpnβ1	 (INI-43	 treatment	
interferes	 with	 the	 localisation	 of	 Kpnβ1	 and	 its	 cargoes),	 little	 is	 known	 about	 the	
specificity	 of	 INI-43	 for	 Kpnβ1.	 Biophysical	 assays	 and	 experiments	 to	 validate	 the	
region/site	 on	 Kpnβ1	 where	 INI-43	 binds	 are	 a	 priority	 for	 future	 research	 in	 the	
laboratory.	The	aim	of	this	chapter	is	therefore	to	preliminarily	assess	the	specificity	of	









Recently	 published	 data	 from	 the	 laboratory	 suggests	 that	 INI-43	may	 be	 acting	 by	
targeting	Kpnβ152.	We	therefore	proposed	that	 if	 INI-43	exerts	 its	anti-cancer	effects	
by	targeting	Kpnβ1,	exogenous	expression	of	Kpnβ1-EGFP	should	rescue	the	inhibitory	
effects	 induced	upon	 INI-43	 treatment.	To	examine	 this,	 the	HeLa	pEFIRES-EGFP	and	
pEFIRES-Kpnβ1-EGFP	 cell	 lines	 described	 in	 Chapter	 3	 were	 used.	 Briefly,	 cells	 were	
treated	 with	 increasing	 concentrations	 of	 INI-43	 and	 dose	 response	 curves	 were	
generated	 to	 calculate	 EC50	 concentrations.	 Treatment	 of	 cells	 with	 Importazole,	 a	
recently	 identified	 small	 molecule	 inhibitor	 of	 Karyopherin	 α/β-mediated	 nuclear	
import60,	and	Doxorubicin,	a	widely	used	anti-cancer	chemotherapeutic113,	were	used	
as	 positive	 and	 negative	 controls,	 respectively.	 Results	 revealed	 that	 HeLa	 pEFIRES-
Kpnβ1-EGFP	 cells	 displayed	 an	 INI-43	 EC50	 value	 that	was	 approximately	 25%	higher	
than	 that	 of	 control	 cells	 (10.4	 µM	 compared	 to	 8.3	 µM)	 (Table	 4.1).	 The	 positive	












































(A)	 and	 Importazole	 (B),	 with	 significantly	 less	 cell	 death	 seen	 in	 Kpnβ1-EGFP	





















































































could	 be	 rescued	 by	 expression	 of	 exogenous	 Kpnβ1,	 the	 localisation	 of	 a	 known	
Kpnβ1	cargo	protein,	NFκB	p6534	was	analysed	by	means	of	an	 immunofluorescence	
assay.	 Our	 results	 show	 that	 p65	 is	 predominantly	 located	 in	 the	 cytoplasm	 of	
untreated	 EGFP	 and	 Kpnβ1-EGFP	 cells	 (Figure	 4.2	 A).	 In	 cells	 stimulated	 with	 the	
phorbol	 ester	 PMA,	 a	nuclear	 translocation	of	 p65	was	 seen.	 Pre-treatment	of	 EGFP	
cells	with	10	µM	INI-43	prevented	the	nuclear	translocation	of	p65.	In	the	case	of	the	
Kpnβ1-EGFP	 cells,	 however,	 a	 nuclear	 localisation	 of	 p65	was	 observed	 despite	 pre-









Figure	 4.2.	 Kpnβ1	 overexpression	 rescues	 the	 inhibitory	 effects	 of	 INI-43	 on	 the	
nuclear	import	of	NFκB	p65.	A:	Immunofluorescence	analysis	of	NFκB	p65	localisation	
in	 control	 (EGFP)	 and	 Kpnβ1	 overexpressing	 (Kpnβ1-EGFP)	 HeLa	 cells	 reveals	
predominantly	 cytoplasmic	 p65	 localisation	 in	 untreated/unstimulated	 cells.	
Treatment	 of	 control	 and	 Kpnβ1-EGFP	 cells	 with	 0.5	 µM	 PMA	 results	 in	 a	 nuclear	
translocation	 of	 p65.	 Pre-treatment	 of	 control	 cells	 with	 10µM	 INI-43	 for	 3	 hours	
prevents	p65	from	entering	the	nucleus	in	response	to	PMA	stimulation,	whereas	the	
nuclear	accumulation	of	p65	is	not	prevented	in	Kpnβ1-EGFP	cells	ie.	p65	is	still	able	to	
enter	 the	 nucleus	 when	 Kpnβ1	 is	 overexpressed.	 Representative	 images	 from	
experiments	performed	three	independent	times	are	shown.	B	and	C:	Quantification	of	
nuclear	 and	 cytoplasmic	 p65	 fluorescence	 in	 approximately	 100	 HeLa	 EGFP	 (B)	 and	
HeLa	 Kpnβ1-EGFP	 (C)	 cells.	 Cells	 were	 scored	 as	 having	 predominantly	 nuclear	 or	
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The	 ability	 of	 Kpnβ1	 to	 rescue	 cells	 from	 the	 inhibitory	 effects	 of	 INI-43	 was	 further	
investigated	 using	 a	 luminescence	 based	 screening	 assay	 in	 which	 a	 NFAT-luciferase	
reporter	 system	was	 transfected	 into	 cells	 and	 used	 to	measure	 nuclear	NFAT	 activity.	
NFAT	(Nuclear	Factor	of	Activated	T	cells)	 is	a	transcription	factor	that	shuttles	between	
the	 nucleus	 and	 cytoplasm	 in	 a	 Kpnβ1-dependent	 manner114.	 NFAT	 is	 predominantly	
cytoplasmic,	but	can	be	stimulated	by	PMA	and	the	calcium	ionophore,	Ionomycin,	to	be	
transported	 into	 the	 nucleus	 upon	 an	 increase	 in	 intracellular	 calcium	 levels.	 Nuclear	
NFAT	activity	can	thus	be	used	as	a	measure	of	functional	Kpnβ1.	To	address	the	question	
of	 whether	 the	 inhibitory	 effects	 of	 INI-43	 on	 NFAT	 activation52	 could	 be	 rescued	 by	
expression	 of	 Kpnβ1-EGFP,	 nuclear	 NFAT	 activity	 was	 assayed	 for	 following	 treatment	
with	 INI-43,	and	 subsequent	 co-stimulation	with	PMA	and	 Ionomycin.	 	Results	 revealed	
that	 stimulation	 of	 NFAT	 transfected	 HeLa	 EGFP	 and	 Kpnβ1-EGFP	 cells	 with	 PMA	 and	
Ionomycin	resulted	in	a	significant	increase	in	activation	of	the	NFAT	reporter,	as	a	result	
of	 NFAT	 nuclear	 import	 (Figure	 4.3).	 Pre-treatment	with	 INI-43	 significantly	 diminished	
NFAT	 activation	 in	 EGFP	 cells,	 but	 not	 in	 Kpnβ1-EGFP	 cells,	 suggesting	 that	 Kpnβ1	























Figure	 4.3.	 Kpnβ1	 overexpression	 rescues	 the	 inhibitory	 effects	 of	 INI-43	 on	 NFAT	
activation.	Graph	showing	the	effect	of	 INI-43	on	NFAT	promoter	activation	 in	control	
(HeLa	EGFP)	and	Kpnβ1	overexpressing	(HeLa	Kpnβ1-EGFP)	cells.	Cells	were	transfected	




with	 INI-43,	 indicating	 that	 there	 is	 still	 significant	 NFAT	 promoter	 activation	 in	 HeLa	
cells	 overexpressing	 Kpnβ1	 despite	 the	 presence	 of	 INI-43.	 Relative	 NFAT	 promoter	
activity	 is	 represented	 as	 a	 percentage	 of	 PMA/Ionomycin	 stimulated	 cells	 (shown	 as	













































Previous	 research	 in	 our	 laboratory	 showed	 that	 INI-43	 treatment	 at	 various	 time	
points	induced	a	G2/M	cell	cycle	arrest	in	HeLa	cells52.	In	order	to	investigate	whether	
Kpnβ1	 overexpression	 rescued	 cells	 from	 an	 INI-43	 induced	 cell	 cycle	 block	 in	 this	
study,	FACS	analysis	was	performed.	Data	reveals	that	the	increase	in	G2/M	observed	







0	μM	 10	μM	 0	μM	 10	μM	
%	G1	 61.6	 52.5	*	 61.4	 60.6	
%	S	 17.2	 16.4	*	 18.0	 16.5	









INI-43.	 D:	 Kpnβ1	 overexpressing	 cells	 show	 no	 significant	 changes	 after	 a	 12	 hour	


























































from	 predominantly	 nuclear	 in	 untreated	 cells,	 to	 cytoplasmic	 and	 nuclear	 in	 INI-43	
treated	 cells	 (Figure	 4.5	 A).	 This	 result	 suggested	 that	 Kpnβ1	 protein	 might	 be	




in	 Kpnβ1	 protein	 degradation,	 cycloheximide	 half-life	 experiments	 were	 performed.	
HeLa	cells	were	pre-treated	with	5	µM	INI-43	 for	 three	hours	and	 then	 treated	with			
40	 µg/ml	 cycloheximide	 (CHX),	 which	 inhibits	 de	 novo	 protein	 synthesis,	 therefore	
allowing	for	analysis	of	protein	degradation	over	time.	Protein	lysates	were	harvested	
at	various	time	points	after	CHX	treatment	and	western	blot	analysis	was	performed	to	
determine	 Kpnβ1	 levels.	 In	 addition	 to	 analysing	 the	 stability	 of	 Kpnβ1,	 additional	
members	 of	 the	 Karyopherin	 protein	 family,	 CRM1	 and	 Kpnα2,	 were	 also	 analysed.	
Western	blot	analysis	revealed	a	reduction	 in	Kpnβ1	protein	stability	after	treatment	
with	 INI-43,	 indicated	 by	 a	 decrease	 in	 Kpnβ1	 protein	 levels,	 whilst	 untreated	 cells	
exhibited	 a	 more	 stable	 Kpnβ1,	 which	 was	 not	 degraded	 during	 the	 time	 course	
(corresponding	with	the	long	Kpnβ1	half-life	that	has	been	reported	in	literature118,119)	
(Figure	4.5	B).		CRM1	and	Kpnα2,	on	the	other	hand,	appeared	to	be	largely	unaffected	




half-life	 was	 equated	 to	 log2/slope.	 The	 half-life	 of	 Kpnβ1	 in	 the	 absence	 of	 INI-43	
treatment	was	 approximately	 33	hours,	while	 in	 the	presence	of	 INI-43	 treatment	 it	
was	 reduced	approximately	 4.7-fold	 to	 7	hours	 (Figure	4.5	C).	 These	 results	 indicate	







Figure	 4.5	 A.	 Treatment	 with	 INI-43	 results	 in	 Kpnβ1	 degradation.	
Immunofluorescence	analysis	showing	Kpnβ1	protein	expression	 in	HeLa	cells	 fixed	3	











were	 pre-treated	 with	 5	 µM	 INI-43	 for	 3	 hours	 and	 then	 treated	 with	 40	 µg/ml	
cycloheximide	(CHX)	and	harvested	for	a	period	of	up	to	24	hours	post	CHX	treatment.	
Western	blot	analysis	shows	a	decrease	in	Kpnβ1	protein	stability	when	cells	are	pre-
treated	 with	 INI-43.	 Other	 members	 of	 the	 Karyopherin	 protein	 family,	 CRM1	 and	
Kpnα2,	 were	 unaffected.	 GAPDH	was	 used	 as	 a	 control	 for	 loading.	 C:	Quantitative	
analysis	 of	 Kpnβ1	 protein	 stability	 in	 the	 absence	 or	 presence	 of	 INI-43	 treatment.	
Western	 blots	 were	 subjected	 to	 densitometric	 scanning	 and	 band	 intensities	 were	
plotted	 in	 log	 scale	 relative	 to	 Kpnβ1	 levels	 at	 time	 zero.	 Kpnβ1	 half-life	 was	

























The	 past	 decade	 has	 seen	 a	 remarkable	 surge	 in	 the	 discovery	 and	 development	 of	
small	 molecule	 anti-cancer	 drugs.	 Conventional	 chemotherapy	 acts	 by	 targeting	 all	
rapidly	 dividing	 cells	 (including	 the	 skin,	 hair	 follicles	 and	 lining	 of	 the	 digestive	
system),	thus	patients	experience	severe	and	undesirable	side	effects.	In	recent	years	
however,	there	has	been	a	shift	towards	a	more	personalised	approach	when	it	comes	






The	 development	 of	 targeted	 anti-cancer	 therapeutics	 requires	 the	 identification	 of	
suitable	 target	 proteins,	 ideally	 ones	 that	 play	 a	 key	 role	 in	 cancer	 cell	 growth	 and	
survival.	The	main	steps	for	successful	discovery	and	development	of	novel	anti-cancer	
drugs	 include:	 Identification	 and	 validation	 of	 a	 molecular	 target;	 high-throughput	
chemical	screening,	hit	identification	and	lead	compound	generation;	lead	compound	
optimisation	 to	 develop	 a	 clinical	 drug	 candidate;	 and	 biomarker-driven	 clinical	
trials120.	 In	 recent	 years,	 targeting	 the	 nuclear	 transport	 machinery	 has	 received	
attention	 as	 a	 promising	 anti-cancer	 approach,	 with	 particular	 focus	 on	 the	 nuclear	
export	protein	CRM1	and	 the	development	of	a	 class	of	novel	Selective	 Inhibitors	of	
Nuclear	 Export	 (SINE	 compounds)121–125.	 Our	 laboratory	 recently	 identified	 a	 novel	
inhibitor	of	 nuclear	 import,	 INI-43,	which	was	designed	as	 a	 lead	 compound	 to	bind	
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and	 inhibit	 Kpnβ152.	 While	 recently	 published	 data	 supports	 the	 use	 of	 INI-43	 as	 a	
cytotoxic	 agent	 that	 shows	 anti-cancer	 activity	 both	 in	 vitro	 and	 in	 vivo,	 limited	
research	has	been	conducted	toward	the	validation	of	INI-43	as	a	Kpnβ1	target.		
	
Drug	 target	 validation	 is	 a	 crucial	 step	 along	 the	 drug	 discovery	 pipeline.	 Many	
biological	 tools	exist	 to	validate	targets,	 including	the	use	of	RNAi,	CRISPR	(Clustered	
Regularly	 Interspaced	 Short	 Palindromic	 Repeats)	 and	 gene	 overexpression,	 in	
combination	with	 small	molecule	 treatment.	 The	 idea	 behind	 these	 techniques	 is	 to	
elucidate	whether	perturbation	of	gene/protein	function	confers	resistance	to	specific	
drugs.	 In	 this	 study,	 we	 used	 exogenously	 expressed	 Kpnβ1-EGFP	 to	 determine	





overexpressed.	Despite	the	 fact	 that	a	significant	amount	of	 rescue	was	seen	 in	cells	
overexpressing	Kpnβ1,	a	complete	restoration	of	function	was	not	observed.	This	was	
particularly	apparent	when	comparing	sensitivity	to	drug;	control	EGFP	cells	exhibited	
an	 INI-43	EC50	 value	of	8.3	µM,	while	Kpnβ1-EGFP	expressing	 cells	 exhibited	an	EC50	
value	of	10.4	µM.	While	these	values	are	significantly	different,	evident	by	their	non-
overlapping	95%	confidence	intervals,	they	both	result	in	death	of	cancer	cells	within	
the	 micromolar	 range.	 It	 is	 therefore	 likely	 that	 while	 INI-43	 is	 in	 part	 acting	 by	
targeting	 Kpnβ1,	 there	 may	 be	 uncharacterised	 off-target	 binding	 of	 the	 drug.	
Alternatively,	 the	 level	 of	 overexpression	 achieved	 using	 the	 HeLa	 pEFIRES-Kpnβ1-
	 88	




Administration	 (FDA)	 to	 treat	 different	 types	 of	 cancer,	 the	 clinical	 effectiveness	 of	
these	targeted	agents	has	been	inconsistent	(largely	due	to	the	development	of	drug	
resistant	 mutations	 in	 tumour	 cells	 resulting	 in	 disrupted	 drug:target	 binding),	 thus	
there	 is	 an	urgent	need	 to	 identify	novel	 strategies	 to	 target	drivers	of	oncogenesis.	
Recently,	the	selective	targeting	of	oncogenic	proteins	for	degradation	has	emerged	as	
an	 attractive	 anti-cancer	 therapeutic	 strategy	 with	 the	 potential	 to	 overcome	 drug	
resistance115,116.	While	recent	results	from	our	laboratory	suggest	that	treatment	with	
INI-43	 results	 in	a	change	 in	Kpnβ1	subcellular	 localisation52,	we	provide	evidence	 in	
this	chapter	that	treatment	with	INI-43	may	be	resulting	in	Kpnβ1	protein	degradation	
as	well.	To	explore	this	further,	we	performed	cycloheximide	half-life	experiments	and	
found	 that	 the	 stability	 of	 Kpnβ1	 was	 reduced	 almost	 5-fold	 in	 cells	 treated	 with							
INI-43.	 These	 results	 demonstrate	 that	 INI-43	 appears	 to	 target	 Kpnβ1	 protein	 for	






viability.	 Alternatively,	 the	 partial	 rescue	 observed	 could	 be	 due	 to	 the	 extent	 of	
overexpression	 achieved	 (approximately	 2-fold,	 or	 a	 1:1	 ratio	 of	 endogenous	 to	
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exogenous	Kpnβ1,	using	the	pEFIRES-Kpnβ1-EGFP	cell	line),	and	thus	greater	levels	of	
overexpression	 might	 provide	 further	 resistance	 to	 INI-43.	 It	 is	 possible	 that	 stable	
overexpression	of	Kpnβ1	allows	for	an	initial	reduction	in	the	toxicities	and	biological	
effects	 induced	 upon	 INI-43	 treatment	 (at	 lower	 concentrations	 of	 INI-43	 there	 is	
sufficient	 ‘unbound’	 Kpnβ1	 for	 cells	 to	 function	 normally),	 however	 at	 higher	












Figure	 4.6.	 Proposed	 model	 for	 the	 partial	 rescue	 of	 Kpnβ1	 function	 at	 low	
concentrations	 of	 INI-43.	 This	 figure	 depicts	 the	 role	 that	 Kpnβ1	 plays	 as	 a	 nuclear	
import	receptor	in	interphase	cells.	INI-43	binds	Kpnβ1,	thereby	preventing	the	binding	
of	Kpnα/cargo	and	subsequent	nuclear	import.	The	same	theory	holds	true	for	the	role	












been	shown	to	play	an	 important	role	 in	 the	regulation	of	various	mitotic	processes,	
such	 as	 mitotic	 spindle	 assembly	 and	 regulation,	 centrosome	 dynamics,	 nuclear	
membrane	 formation	and	nuclear	pore	assembly,	where	 in	most	 cases	 it	 is	 counter-
regulated	by	the	small	regulatory	GTPase,	Ran22.	
	
Eukaryotic	 cells	 undergo	 division	 by	 cycling	 between	 interphase	 and	mitosis.	 Kpnβ1	
acts	positively	in	interphase,	as	a	nuclear	import	protein	and	potential	motor	adaptor	
for	 movement	 along	 the	 microtubules22,68.	 In	 contrast,	 Kpnβ1	 plays	 a	 negative	
regulatory	 role	 in	 mitosis,	 preventing	 spatially	 inappropriate	 spindle	 formation,	 by	
binding	 and	 masking	 the	 activity	 of	 spindle	 assembly	 factors	 (SAFs)	 in	 cytoplasmic	
areas	 distant	 from	 the	 chromatin	 until	 high	 levels	 of	 RanGTP	 near	 the	 mitotic	
chromosomes	result	in	release	of	the	SAFs,	thereby	setting	spindle	assembly,	and	thus	
mitosis,	 in	 motion68,126.	 Kpnβ1	 has	 also	 been	 shown	 to	 be	 involved	 in	 spatially	
controlling	the	major	assembly	events	of	late	mitosis,	such	as	nuclear	membrane	and	
nuclear	 pore	 assembly,	 with	 the	 Kpnβ1/RanGTP	 balance	 having	 been	 shown	 to	 be	
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crucial	 in	 the	 regulation	 of	 the	 vesicle-vesicle	 fusion	 reaction	 that	 is	 required	 for	
double	 nuclear	 membrane	 formation95.	 	 Excess	 Kpnβ1	 in	 the	 system	 has	 an	
overwhelming	effect	on	the	amount	of	RanGTP	present,	resulting	in	the	sequestration	
of	SAFs	(even	those	close	to	the	mitotic	chromosomes),	thus	preventing	the	formation	
of	 the	 mitotic	 spindle	 and	 inhibiting	 correct	 nuclear	 membrane	 and	 nuclear	 pore	
formation22,95.	 In	 contrast,	 excess	 RanGTP	 causes	 untimely	 release	 of	 Kpnβ1	 which	
results	 in	 uncontrolled	 microtubule	 nucleation	 and	 formation	 of	 hyperabundant,	
invaginated	 nuclear	membranes	 around	 the	 chromatin68.	 Thus,	 a	 precise	 balance	 of	
Kpnβ1/RanGTP	activity	is	essential	for	correct	mitotic	functioning.	
	
Previous	 studies	 have	 shown	 that	 disruption	 of	 Kpnβ1	 expression	 (by	 loss	 of	
endogenous	Kpnβ1	through	siRNA-mediated	knockdown,	or	 transient	overexpression	
of	 Kpnβ1	 using	 plasmid-based	 transfection),	 resulted	 in	 the	 appearance	 of	 distinct	
mitotic	defects,	such	as	multipolar	spindles,	chromosome	misalignment,	and	lagging	or	
mis-segregation	 of	 chromosomes	 in	 anaphase/telophase87,90,96.	 In	 this	 study,	 we	
independently	 validated	 and	 expanded	 on	 this	 work	 by	 investigating	 whether	
dysregulation	of	Kpnβ1	(mediated	by	inducible	expression	of	exogenous	Kpnβ1-EGFP,	
or	 by	 drug-mediated	 inhibition	 of	 Kpnβ1	 using	 the	 novel	 small	 molecule	 inhibitor,				
INI-43)	 resulted	 in	 the	 appearance	 of	 mitotic	 defects,	 by	 performing	 time-lapse	
analysis	of	HeLa	TET-ON	Kpnβ1-EGFP	cells	as	they	progress	through	the	cell	cycle.		
	
This	 study	was	 carried	out	as	part	of	an	 international	exchange	 in	Dr	Patrizia	 Lavia’s	
laboratory	 at	 the	 Sapienza	University	 of	 Rome.	 The	work	was	 completed	 over	 three	
months,	 between	 December	 2015	 and	 March	 2016.	 Much	 of	 the	 work	 done,	 and	
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systems	 used	 (ie.	 the	 HeLa	 TET-ON	 Kpnβ1-EGFP	 cells),	 are	 part	 of	 a	 larger	 research	








In	 Chapter	 3,	 the	 effects	 associated	 with	 stable	 expression	 of	 Kpnβ1-EGFP	 were	
investigated.	 Kpnβ1-EGFP	 was	 overexpressed	 at	 an	 approximate	 1:1	 ratio,	 and	 this	
resulted	in	the	various	biological	changes	described.	In	this	chapter,	to	investigate	the	
effects	of	 continuous	 induction	of	Kpnβ1	overexpression	 in	HeLa	cells,	 a	 stable	HeLa	
cell	 line	 in	which	 Kpnβ1-EGFP	 can	 be	 inducibly	 expressed	was	 used,	 known	 as	HeLa	
TET-ON	 Kpnβ1-EGFP	 (generated	 by	 Annalisa	 Verrico	 and	 Patrizia	 Lavia,	 Institute	 of	
Molecular	Biology	and	Pathology,	National	Research	Council	of	 Italy,	Rome,	 Italy).	To	
confirm	 induction	 of	 Kpnβ1-EGFP,	 cells	were	 incubated	with	 1	µg/ml	 doxycycline	 to	
stimulate	 the	 tetracycline	 responsive	promoter,	 and	 live	 cell	 time-lapse	 fluorescence	
videomicroscopy	was	performed	to	analyse	GFP	 intensity	over	time.	Results	revealed	
that	 in	 the	 presence	 of	 doxycycline,	 Kpnβ1-EGFP	 accumulated	 to	 approximately									
1.5	times	that	of	endogenous	Kpnβ1	by	24	hours	post	induction	(Figure	5.1).	This	was	
greater	 overexpression	 than	 that	 observed	 with	 stable	 expression	 of	 the	 pEFIRES	
plasmid,	 which	 expressed	 Kpnβ1-EGFP	 at	 levels	 roughly	 equivalent	 to	 endogenous	
Kpnβ1	(Chapter	3).	Using	time-lapse	videomicroscopy	to	analyse	cell	death,	our	results	







mitosis	 (Death	 after	 M).	 Cells	 overexpressing	 Kpnβ1	 (up	 to	 1.5	 times	 that	 of	
endogenous	Kpnβ1)	underwent	cell	death	during	interphase	or	mitosis,	as	well	as	after	





Figure	 5.1.	 Kpnβ1-EGFP	 induction	 after	 doxycycline	 treatment	 is	 continous.	
Quantification	of	GFP	intensity	(measured	in	the	FITC	fluorescent	channel)	for	up	to	24	
hours	 post	 induction	 of	 HeLa	 TET-ON	 Kpnβ1-EGFP	 cells	 with	 1	 µg/ml	 doxycycline									
(±	 DOX).	 Fluorescence	 intensity	was	 recorded	 by	 analysing	 cells	 over	 a	 period	 of	 24	
hours	using	time-lapse	videomicroscopy.	FITC	images	were	acquired	every	60	minutes	


































Figure	 5.2.	 Continuous	 induction	 of	 Kpnβ1	 results	 in	 significant	 cell	 death.	
Quantification	 of	 cell	 death,	 classified	 as	 either	 death	 in	 interphase	 or	 first	 mitosis	
(white	bars),	or	death	of	daughter	cells	after	first	mitosis	(black	bars),	and	shown	as	a	
percentage	of	total	recorded	phenotypes	observed	up	to	and	including	8	hours	and	24	





































Previous	 studies	 have	 shown	 that	 dysregulation	 of	 Kpnβ1	 expression,	 by	 using	
transient	 overexpression	 of	 Kpnβ1-EGFP	 as	 well	 as	 siRNA-mediated	 knockdown	 of	
Kpnβ1,	 resulted	 in	 the	 appearance	 of	 distinct	 mitotic	 defects,	 suggesting	 the	
importance	of	maintaining	a	tight	regulation	of	Kpnβ1	for	correct	mitotic	functioning	
to	occur90,96.	To	 further	our	understanding	of	 the	 links	between	Kpnβ1	dysregulation	
and	 genomic	 instability,	 we	 investigated	 the	 effects	 of	 inducible	 overexpression	 of	






pre-treated	 with	 1	 µg/ml	 doxycycline	 for	 a	 period	 of	 4	 hours,	 in	 order	 to	 induce	
expression	 of	 Kpnβ1-EGFP.	 Following	 doxycycline	 treatment,	 cells	were	 treated	with	
INI-43	for	a	period	of	3	hours	(in	the	continued	presence	of	doxycycline),	as	this	had	
been	 previously	 established	 as	 being	 sufficient	 to	 cause	 inhibition	 of	 Kpnβ1	without	
resulting	in	significant	cell	death	within	the	three	hour	period52.	After	treatment,	cells	
were	washed	 and	media	was	 replaced	with	 TET-free	 DMEM	 (minus	 phenol	 red	 -	 to	




time-lapse	 recording.	 Cells	 were	 recorded	 for	 a	 period	 of	 24	 hours;	 Differential	
Interference	Contrast	(DIC)	 images	were	acquired	every	15	minutes,	and	FITC	 images	
(for	analysis	of	GFP	signal)	every	60	minutes,	using	a	DS-Qi1Mc	camera	and	the	NIS-







Figure	 5.3.	 Experimental	 workflow	 for	 time-lapse	 vidoemicroscopy.	 Time-lapse	
analysis	 of	 HeLa	 TET-ON	 Kpnβ1-EGFP	 cells.	 25	 000	 cells	 were	 seeded	 in	 8-well	 Ibidi	
micro	slides	and	allowed	 to	adhere	overnight.	After	24	hours,	 cells	were	pre-treated	
with	1	µg/ml	doxycycline	(DOX)	for	a	period	of	4	hours,	in	order	to	induce	expression	
of	 Kpnβ1-EGFP.	 Following	 doxycycline	 treatment,	 cells	 were	 treated	 with	 varying	
concentrations	 of	 INI-43	 (0,	 5	 or	 10	µM)	 for	 a	 period	 of	 3	 hours	 (in	 the	 continued	
presence	of	doxycycline),	after	which	cells	were	washed	and	media	was	replaced	with	
TET-free	DMEM	(no	phenol	red)	supplemeted	with	0.5	µg/ml	doxycycline.	Cells	were	

















(by	 either	 doxycycline-induced	 expression	 of	 Kpnβ1-EGFP,	 or	 INI-43	 mediated	
inhibition	of	Kpnβ1)	resulted	in	the	appearance	of	spindle	and	chromosome-associated	
mitotic	 abnormalities.	 Multipolar	 spindles,	 spindle	 axis	 rotation,	 and	 delay	 in	




of	 mitotic	 abnormalities,	 which	 were	 grouped	 into	 two	 broad	 categories:	 structural	






In	 addition	 to	 studying	 the	 negative	 effects	 of	 Kpnβ1	 dysregulation	 on	 cell	 cycle	





lagging	 chromosomes	 (Figure	 5.7	 B).	 These	 defects	 were	 quantified,	 and	 an	






















frame	 images	are	 shown;	 time	 from	beginning	of	 time-lapse	 is	 indicated	 in	minutes.	
Various	 abnormal	 phenotypes	 were	 recorded	 and	 captured.	 The	 most	 common	
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to	 overexpress	 Kpnβ1.	 The	 frequency	 of	 mitotic	 abnormalities	 observed	 in	 each	
condition	were	counted,	and	recorded	as	a	percentage	of	total	recorded	phenotypes	
over	 a	 period	 of	 24	 hours.	Uninduced	 cells	 (-	 DOX)	were	 compared	 to	 cells	 induced	
with	1	µg/ml	doxycycline	to	express	Kpnβ1-EGFP	(+	DOX).		M	–	mitotic.	Results	shown	



















































































fixed	 cells.	 A:	 Experimental	 workflow	 for	 immunofluorescence	 analysis	 of	 fixed	 cells.	 After	
induction	with	doxycycline	or	treatment	with	INI-43,	cells	were	fixed	using	4%	paraformaldehyde.								
B:	 Representative	 images	 are	 shown	 for	 the	mitotic	 abnormalities	 induced	 by	 dysregulation	 of	
Kpnβ1	(doxycycline-induced	overexpression	or	INI-43	mediated	inhibition)	in	HeLa	TET-ON	Kpnβ1-
EGFP	cells.	Fixed	cells	were	stained	with	DAPI	(blue,	panel	2)	and	α-Tubulin	(red,	panel	3).	Merged	
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across	 the	 various	 treatment	 conditions	 was	 analysed.	 Using	 the	 data	 obtained	 by	
time-lapse	 analysis,	 the	 median	 time	 of	 cell	 division	 was	 calculated,	 and	 it	 was	





showing	 that	 the	dysregulation	of	Kpnβ1	 is	associated	with	 the	disruption	of	mitotic	
events90,96.	As	the	mitotic	defects	induced	upon	INI-43	treatment	were	similar	to	those	








Figure	 5.8.	 Kpnβ1	 dysregulation	 leads	 to	 prolonged	 mitotic	 progression.	 Box	 and	
whisker	 plots	 display	 median	 duration	 of	 mitosis	 of	 HeLa	 TET-ON	 Kpnβ1-EGFP	 cells	
induced	to	overexpress	Kpnβ1	using	1	µg/ml	doxycycline	(A)	or	treated	with	5	µM	and	















HeLa	 cells	 stably	 overexpressing	 Kpnβ1	were	 treated	with	 varying	 concentrations	 of	
INI-43)	 could	 be	 observed,	 HeLa	 TET-ON	 Kpnβ1-EGFP	 cells	 were	 induced	 with	
doxycycline	for	4	hours,	followed	by	treatment	with	INI-43	(in	the	continued	presence	
of	doxycycline)	for	a	period	of	3	hours.	Analysis	of	time-lapse	recordings	revealed	that	
induction	 of	 Kpnβ1-EGFP	 expression	with	 doxycycline	 resulted	 in	 an	 increase	 in	 the	
appearance	 of	 mitotic	 abnormalities	 as	 previously	 described.	 Treatment	 of	 Kpnβ1-
EGFP	 expressing	 cells	 with	 5µM	 INI-43	 resulted	 in	 a	 significant	 rescue	 in	 the	
percentage	of	mitotic	abnormalities	observed	(Figure	5.9),	thus	a	larger	proportion	of	
cells	 underwent	normal	division.	 Similarly,	 a	 significant	 reduction	 in	mitotic	duration	
was	observed	when	cells	overexpressing	Kpnβ1	were	treated	with	INI-43	(Figure	5.10).	







in	 the	 appearance	 of	mitotic	 abnormalities.	 The	 frequency	of	mitotic	 abnormalities	
was	 counted,	 and	 recorded	 as	 a	 percentage	 of	 total	 recorded	 cells.	 Untreated	HeLa	
TET-ON	Kpnβ1-EGFP	 cells	 induced	 to	 overexpress	 Kpnβ1	 (+	DOX)	were	 compared	 to	
cells	 induced	 to	 overexpress	 Kpnβ1	 and	 treated	 with	 5	 µM	 INI-43.	 Results	 shown	
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doxycycline	 (+	DOX)	and	treated	with	5	µM	INI-43.	At	 least	 fifty	divisions	 from	three	
independent	experiments	were	scored	for	each	condition	(*	p	<	0.05).	






protein.	 It	 was	 not	 until	 more	 recently	 that	 Kpnβ1	 has	 emerged	 as	 playing	 roles	 in	
multiple	other	cellular	processes.	In	addition	to	its	function	in	nuclear	transport,	Kpnβ1	
has	a	wide	 range	of	 important	 roles	 in	mitosis,	 spanning	 from	the	control	of	 spindle	
assembly	and	centrosome	dynamics,	 to	 the	 regulation	of	nuclear	envelope	and	pore	
assembly.	 Research	 by	 various	 groups	 has	 revealed	 that	 Kpnβ1	 dysregulation	 (by	
ectopic	 overexpression	 and	 RNAi-mediated	 protein	 knockdown)	 resulted	 in	 the	




resulted	 in	 defects	 in	 spindle	 pole	 organisation87,	 and	 Roscioli	 et	 al.	 (2012)	 later	
showed	 that	 Kpnβ1	 overexpression	 induced	 various	 mitotic	 abnormalities	 such	 as	
multipolar	 division,	 chromosome	misalignment	 and	 significant	mitotic	 delay	 in	 HeLa	
cells96.	More	recently	in	our	laboratory,	Angus	et	al.	(2015)	revealed	that	inhibition	of	
Kpnβ1	 protein	 expression	 by	 siRNA	 in	 cervical	 cancer	 cells	 resulted	 in	 a	 prolonged	
mitotic	arrest,	which	was	accompanied	by	the	a	similar	set	of	mitotic	defects	to	those	
observed	with	Kpnβ1	overexpression90.	In	this	chapter,	we	set	forth	to	independently	
validate	 these	 findings	 using	 two	 separate	modes	 of	 Kpnβ1	 dysregulation:	 inducible	
expression	 of	 exogenous	 Kpnβ1-EGFP,	 and	 INI-43	 mediated	 inhibition	 of	 Kpnβ1.	 In	
addition,	 the	 specificity	 of	 INI-43	 for	 Kpnβ1	 was	 reassessed	 using	 the	 HeLa	 TET-ON	
Kpnβ1-EGFP	cell	line.	
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Previous	 studies	 indicate	 that	 depending	 on	 the	 levels	 of	 Kpnβ1	 overexpression,	
various	 biological	 effects	 may	 be	 observed.	 For	 example,	 while	 high	 doses	 of	
exogenous	Kpnβ1	in	HeLa	cells	yielded	a	low	mitotic	index	and	arrest	in	G2/M	phase	of	
the	 cell	 cycle,	 moderate	 levels	 of	 exogenous	 Kpnβ1	 (cells	 shown	 to	 express	 an	
approximate	 1:1	 ratio	 of	 exogenous	 to	 endogenous	 protein),	 despite	 resulting	 in	 no	
significant	 arrest,	 revealed	distinct	mitotic	 abnormalities87,96.	 The	primary	 interest	 of	
these	 studies	 was	 in	 elucidating	 the	 role	 of	 Kpnβ1	 in	 mitosis;	 hence	 the	 effects	
associated	with	varying	exogenous	Kpnβ1	dosage	on	other	biological	processes,	such	
as	cell	proliferation,	were	not	determined	at	 the	time.	We	showed	 in	Chapter	3	 that	
stably	 expressing	 Kpnβ1-EGFP	 at	 levels	 approximately	 equivalent	 to	 that	 of	
endogenous	 Kpnβ1	 (ie.	 a	 1:1	 ratio)	 resulted	 in	 only	 a	 minor	 reduction	 in	 the	
proliferation	of	cancer	cells,	 likely	due	to	an	observed	delay	 in	cell	cycle	progression.	




upregulated	beyond	a	1:1	 ratio	of	 endogenous	 to	 exogenous	protein,	 significant	 cell	
death	 was	 observed.	 This	 leads	 to	 the	 conclusion	 that	 a	 tight	 regulation	 of	 Kpnβ1	
expression	 is	 required,	 as	 cells	 appear	 to	 be	 unable	 to	 handle	 the	 negative	 effects	
associated	with	dysregulation	of	Kpnβ1	past	a	certain	threshold.	
	
While	 a	 few	 studies	 have	 shown	 evidence	 that	 dysregulation	 of	 Kpnβ1	 leads	 to	 the	
accumulation	 of	 various	 mitotic	 defects,	 results	 are	 based	 only	 on	 transient	








seen	 in	 cells	 induced	 to	 overexpress	 Kpnβ1,	 treatment	 of	 HeLa	 cells	 with	 INI-43	
resulted	in	a	dose-dependent	 increase	in	the	appearance	of	mitotic	defects.	Previous	
experiments	 in	which	Kpnβ1	was	 inhibited	via	RNAi	showed	similar	results	 to	that	of	
INI-43	 treated	 cells90,	 suggesting	 that	 INI-43	 is	 acting	 in	 a	 similar	 manner	 to	 Kpnβ1	
protein	knockdown,	thus	implying	that	it	acts	by	targeting	Kpnβ1.				
	
In	 mitosis,	 Kpnβ1	 acts	 as	 a	 negative	 regulator	 of	 various	 processes.	 For	 example,	
during	 spindle	 assembly	 it	 acts	 by	 sequestering	 SAFs	 at	 areas	 distant	 to	 mitotic	
chromosomes,	thereby	preventing	untimely	mitotic	progression.	RanGTP	on	the	other	
hand	acts	as	a	positive	regulator,	counteracting	the	activity	of	Kpnβ1	by	releasing	SAFs	
and	 allowing	 spindle	 assembly	 to	 occur.	 Overexpression	 of	 Kpnβ1	 results	 in	
sequestration	 of	 SAFs	 (even	 those	 close	 to	 the	 mitotic	 chromosomes)	 and	 thus	
prevents	 the	 formation	 of	 the	 mitotic	 spindle22,95.	 Inhibition	 of	 Kpnβ1	 results	 in	
premature	 release	 of	 SAFs	 and	 activation	 of	 excessive	 mitotic	 spindle	 formation;	
overexpression	of	TPX2,	a	major	SAF	in	mammalian	cells,	has	been	shown	to	result	in	
significant	 mitotic	 spindle	 defects87.	 Therefore,	 the	 appearance	 of	 mitotic	





acts	 by	 targeting	 Kpnβ1	 (at	 least	 in	 part),	 rescue	 experiments	 were	 performed.	We	
found	that	the	treatment	of	cells	induced	to	express	Kpnβ1-EGFP	with	INI-43	resulted	
in	a	significant	reduction	 in	the	appearance	of	mitotic	abnormalities	seen	with	either	
condition	 alone.	 Research	 by	 the	 Lavia	 group	 suggests	 that	 Kpnβ1	 overexpression	
leads	to	the	sequestration	of	NLS-containing	mitotic	factors,	which	ultimately	results	in	
the	 appearance	 of	 certain	 structural	 (spindle	 organisation	 and	 chromosome	
segregation)	abnormalities87,96.	It	appears	as	if	these	negative	effects	can	to	an	extent	
be	 mitigated	 when	 cells	 are	 treated	 with	 INI-43,	 suggesting	 that	 INI-43	 is	 targeting	
Kpnβ1	and	thus	allowing	for	restoration	of	activity	of	the	cargoes.	
Overall,	our	results	suggest	that	when	treating	Kpnβ1	overexpressing	cells	with	INI-43,	
a	 partial	 rescue	 effect/restoration	 of	 function	 is	 observed.	 Interestingly,	 treatment	
with	higher	concentrations	of	INI-43	did	not	have	the	same	rescue	effect,	possibly	due	
the	 fact	 that	 the	 system	 has	 become	 overwhelmed;	 this	 ties	 in	 with	 the	 proposed	
model	for	the	partial	rescue	of	Kpnβ1	function	in	Chapter	4	(Figure	4.7).		
Ultimately,	 the	 results	 displayed	 in	 this	 chapter	 support	 previous	 data	 showing	 that	
dysregulation	of	Kpnβ1	is	associated	with	the	disruption	of	mitotic	events,	and	suggest	
that	 a	 tight	 regulation	 of	 Kpnβ1	 is	 essential	 for	 the	 correct	 functioning	 of	 cells.	 In	








Dysregulation	 of	 the	 nuclear	 transport	 machinery	 has	 been	 directly	 linked	 to	





remains	 unclear	 as	 to	 whether	 Kpnβ1	 induces	 any	 features	 of	 the	 transformed	 or	
cancer	 phenotype.	 In	 this	 study,	we	 addressed	 the	 role	 that	 Kpnβ1	 plays	 in	 various	
biological	processes	associated	with	cellular	transformation	and	cancer	progression,	by	
studying	 the	 effects	 associated	 with	 dysregulation	 of	 Kpnβ1	 (by	 exogenous	
overexpression	and/or	small	molecule-mediated	inhibition)	in	cancer	cells.	In	addition,	
the	 specificity	of	 the	 small	molecule	 inhibitor,	 INI-43,	 for	Kpnβ1	was	 investigated	by	
using	expression	of	exogenous	Kpnβ1-EGFP	as	a	rescue	mechanism.	




including	 a	 reduction	 in	 cell	 proliferation	 and	 delay	 in	 cell	 cycle	 progression	 after	
synchronisation.	Previous	research	conducted	using	HeLa	cells	showed	that	depending	
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on	 the	 levels	 of	 Kpnβ1	 overexpression,	 various	 effects	 (that	 increased	 in	 severity	
according	 to	 the	 level	 of	 overexpression)	 were	 observed87,96.	 In	 this	 study,	 stable	
expression	 of	 Kpnβ1-EGFP	 at	 levels	 higher	 than	 those	 achieved	 using	 the	 pEFIRES	
plasmid	 could	 not	 be	 attained	 due	 to	 high	 levels	 of	 cell	 death.	 It	 is	 likely	 that	 the	
effects	seen	in	Chapter	3	are	as	a	result	of	only	moderate	expression	of	Kpnβ1-EGFP	in	
the	pEFIRES	stable	cell	lines	(resulting	in	relatively	mild	phenotypic	changes),	and	that	




is	 believed	 that	 a	 precise	 balance	 of	 their	 activity	 is	 essential	 for	 the	 correct	
functioning	 of	 various	 biological	 processes;	 indeed	 a	 number	 of	 studies	 have	 shown	
this68,87,95.	We	therefore	hypothesised	that	the	negative	effects	found	to	be	associated	
with	 overexpression	 of	 Kpnβ1	might	 be	 rescued	 by	 the	 co-expression	 of	 exogenous	
Ran.	This	was	not	the	case	in	our	study	however;	we	observed	that	overexpression	of	
Ran	 in	 cells	 already	 overexpressing	 Kpnβ1	 appeared	 to	 disturb	 the	 balance	 even	













not	 increase	 the	 proliferation	 rate	 of	 normal	 fibroblast	 cells,	 indicating	 that	
overexpression	 of	 Kpnβ1	 alone	 is	 likely	 unable	 to	 drive	 cellular	 transformation.	 It	 is	
possible	 that	 Kpnβ1	 upregulation	 is	 not	 a	 driver,	 but	 rather	 a	 product	 of	 cellular	
transformation	 and	 tumour	 progression;	 it	 is	 necessary	 but	 not	 sufficient	 for	 cancer	
development.	 A	 number	 of	 examples	 of	 genes	 that	 are	 required	 for	 cancer	 cell	
proliferation	but	are	not	sufficient	to	 induce	malignant	transformation	are	present	 in	
the	 literature,	 including	Cks1128	and	JNK129.	There	 is	a	possibility	 that	upregulation	of	
the	nuclear	 transport	 family	 as	 a	whole	might	have	 greater	 ability	 to	 induce	 cellular	
transformation,	as	its	appears	as	if	the	upregulation	of	Kpnβ1	in	cancer	cells	does	not	
occur	 in	 isolation,	 but	 rather	 alongside	 the	upregulation	of	 a	myriad	of	 other	 family	
members	(unpublished	observations).		
	
Rescue	 experiments	 performed	 using	 exogenous	 Kpnβ1-EGFP	 revealed	 that	
overexpression	of	Kpnβ1	significantly	rescued	the	negative	effects	observed	when	cells	
were	treated	with	INI-43.		Furthermore,	overexpression	of	Kpnβ1	or	treatment	of	cells	
with	 INI-43	 resulted	 in	 a	 similar	 set	 of	 mitotic	 defects,	 that	 could	 be	 significantly	
rescued	when	 cells	 expressing	 Kpnβ1-EGFP	were	 treated	with	 INI-43.	 	 These	 results	
imply	 that	 INI-43	exerts	 its	effects,	at	 least	 in	part,	by	 targeting	Kpnβ1.	 Interestingly,	
when	 Kpnβ1	 was	 overexpressed	 beyond	 levels	 achieved	 using	 the	 pEFIRES-Kpnβ1-
EGFP	 stable	 cell	 line	 (by	 the	 use	 of	 a	 continuous	 Kpnβ1-EGFP	 expression	 system	 in	
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Chapter	 5),	 a	 significant	 induction	 of	 cell	 death	 was	 observed.	 Inhibition	 of	 Kpnβ1	
protein	expression	using	siRNA14,	or	 treatment	of	 cancer	cells	with	 INI-4352,	 similarly	
resulted	 in	 increased	 cell	 death,	 suggesting	 that	 cancer	 cells	 cannot	 cope	 with	
dysregulation	on	Kpnβ1	expression	beyond	a	certain	threshold.		
Taken	 together,	 this	 study	 provides	 evidence	 that	 a	 precise	 balance	 of	 Kpnβ1	
expression	(and	activity)	 is	crucial	for	cancer	cell	proliferation	and	survival.	When	the	
balance	is	perturbed	in	either	direction	(i.e.	with	overexpression	of	Kpnβ1	or	inhibition	
of	 Kpnβ1	 [that	 can	be	 via	 siRNA-mediated	 knockdown14	or	 small	molecule-mediated	
inhibition,	 such	 as	 that	 with	 INI-4352],	 negative	 effects	 associated	 with	 various	
biological	 phenotypes	 are	 observed.	 These	 include:	 reduced	 proliferation	 (and	
induction	of	 apoptosis	when	Kpnβ1	 is	 dysregulated	beyond	 certain	 levels),	 cell	 cycle	




Ultimately,	 the	 results	 presented	 in	 this	 dissertation	 provide	 evidence	 that	 a	 tight	
regulation	 of	 Kpnβ1	 is	 essential	 for	 the	 correct	 functioning	 of	 cancer	 cells,	 thus	
highlighting	 the	 potential	 for	 Kpnβ1	 as	 a	 promising	 anti-cancer	 therapeutic	 target.	
Furthermore,	rescue	experiments	confirm	that	the	small	molecule	inhibitor,	 INI-43,	 is	
acting	(at	least	in	part)	by	targeting	Kpnβ1.	We	propose	that	further	modification	and	















A	 major	 limitation	 of	 this	 study	 was	 the	 lack	 of	 data	 for	 the	 effects	 of	 Kpnβ1	
overexpression	in	non-cancer	cell	lines.	Despite	optimisation	of	transfection	conditions	





the	 future	 we	 hope	 to	 be	 able	 to	 further	 investigate	 the	 role	 of	 Kpnβ1	 in	 cellular	
transformation	 and	 tumourigenesis	 by	 studying	 the	 effects	 of	 Kpnβ1	 dysregulation	
along	various	stages	of	the	transformation	process	-	 i.e.	through	the	use	of	a	tumour	
progression	 model	 such	 as	 the	 MCF10	 breast	 tumour	 progression	 series	 used	 by	
Kuusisto	and	Jans	(2015)73.		
While	 rescue	 experiments	 using	 expression	 of	 exogenous	 Kpnβ1-EGFP	 suggest	 that	
INI-43	 acts	 partly	 by	 targeting	 Kpnβ1,	 further	 investigation	 is	 required	 to	 determine	
binding	and	specificity.		We	propose	performing	molecular	docking	studies	to	identify	
potential	 binding	 site(s)	 for	 INI-43	 on	 Kpnβ1,	 after	 which	 mutational	 studies	 and	
biophysical	 assays	will	 be	used	 to	 confirm	binding	by	 identifying	potential	 resistance	
causing	 mutations.	 The	 mechanism	 of	 INI-43	 mediated	 degradation	 of	 Kpnβ1	 also	




There	 is	 sufficient	 evidence	 that	 targeting	 Kpnβ1	 has	 therapeutic	 potential	 for	 the	
treatment	of	cancer,	and	that	INI-43	may	be	useful	as	a	lead	compound	for	the	future	
development	 of	 Kpnβ1	 inhibitors	 that	 are	 clinically	 relevant52.	 	 We	 propose	 that	


































































































































































































Figure	A.1.	 KAPA	Universal	 DNA	 ladder.	 Ladder	used	 to	determine	 the	molecular	weight	of	
plasmid	DNA	after	restriction	enzyme	digest.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	A.2.	Colour	Prestained	Protein	Standard.	Ladder	used	to	determine	the	molecular	
weight	of	proteins	electrophoresed	on	10	-15%	SDS-PAGE	gels.	
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